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Sarcomas are rare mesenchymal tumors, making up 15% of all childhood and 1% of all adult
tumors. They account for a disproportionate share of mortality in young adults, and if left
untreated, are highly likely to metastasize. However, sarcoma etiology is poorly
understood, and having numerous histological subtypes has complicated elucidation. To
better understand factors underlying sarcomagenesis, we leveraged two rare inherited
cancer predisposition syndromes, Li-Fraumeni Syndrome (LFS), and LFS-like (LFSL), both
with a high incidence of sarcomas. LFS is caused by mutations in the tumor suppressor gene
TP53 (p53), but has variable and incomplete penetrance, suggesting additional acquired
somatic mutations are necessary for tumorigenesis. In contrast, LFSL has no known cause,
although a 10-Mb region in 1q23 has been mapped by linkage analysis as a putative LFSL
locus. Therefore, to better identify genetic variation underlying LFS and LFSL we utilized a
2-pronged approach. First, we evaluated LFSL families for rare, co-segregating, germline
mutations, which identified a mutation in ARHGAP30 that was present in four LFSL families.
Moreover, this mutation impacted both proliferation and migration when overexpressed in
vitro. Subsequent analysis of publicly available data indicates a potential role for ARHGAP30
iii

in sporadic cancers. Secondly, we endeavored to identify somatically acquired drivers of
sarcomagenesis. In cancer, passenger events are acquired concomitantly with driver
mutations, and distinguishing them remains a key challenge. To best address this, we used
a comparative genomics approach, leveraging a “humanized” mouse model of LFS with a
hotspot mutation, Trp53R172H, analogous to TP53R175H in humans. Hypothesizing that
sarcoma etiology is similar in humans and mice, we then catalogued recurrent changes in
the genome, transcriptome, and methlyome. We found little overlap in any of the omics
approaches across the human tumors, which came from diverse p53 mutations and
sarcoma types, but found strong overlap in the mouse tumors (fibrosarcomas and
osteosarcomas). Recurrent data discovered in the mouse was mirrored in some human
sporadic mesenchymal tumors, including novel genes like MROH2A, and MIR219A2. Our
results emphasize the utility of a model disorder and comparative omics to uncover genes
with relevance for both inherited and sporadic tumors.
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1 Introduction
1.1

Introduction to cancer
Cancer is a multifactorial genetic and epigenetic disease characterized by abnormal,

unchecked cell growth. Cells typically progress gradually through a series of steps, from
hyperplasia, to dysplasia, to neoplasia, and sometimes malignancy, usually driven by genetic
changes, that disrupt core processes that normally help regulate cell growth.

These

processes have been categorized into ten distinct functions, known as “the Hallmarks of
Cancer.” Initially, Hanahan and Weinberg postulated that cancer cells might have additional
capabilities across six different categories: sustained growth signaling, evasion of growth
suppressors, resistance to cell death, induction of angiogenesis, enabling of replicative
immortality, and activation of invasion and metastasis (Figure 1) (1).
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Figure 1: Hallmarks of Cancer. Original six canonical ways that cancer cells have added
abilities (2). Used with permission: Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of
cancer: the next generation. Cell 144: 646-674. L/N 4294491470430.
Subsequent research has strongly indicated two other hallmarks: deregulating cellular
energetics, and avoiding immune destruction, and two enabling characteristics: genome
instability and mutation, and tumor-prone inflammation (Figure 2) (2).
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Figure 2: Hallmarks of Cancer, updated. In 2011, the hallmarks were updated to include
two new emerging hallmarks, and two enabling characteristics (2). Used with permission:
Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell
144: 646-674. L/N 4294491470430.
These ideas provide a framework for understanding how tumors might arise, and how
they differ from normal cells.
The changes necessary for tumorigenesis can be acquired in a variety of ways. In
cancer predisposition syndromes, germline mutations can be inherited from the parents.
Alternatively, changes in the genome can be acquired somatically, either from errors during
cell division, or from exposure to environmental mutagens such as smoking or UV rays. For
example, in microsatellite instability syndromes, such as Lynch Syndrome, during
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replication, defects in mismatch repair genes lead to DNA polymerase slippage, frameshift
mutations and non-functional proteins (3). However, not all such changes may be cancercausing; some alterations that are acquired may instead be passengers, with limited or even
no functional impact.

Distinguishing cancer-causing driver mutations from passenger

events remains a key challenge in understanding cancer etiology (4).
Beyond just looking for genetic changes in the genome, we increasingly find that
changes in the transcriptome and epigenome can also lead to disease, including cancer (57). Moreover, this makes integrative approaches that seek to completely profile tumors
across the genome, transcriptome, and epigenome uniquely powerful to quantify, and
evaluate as many changes as possible (7). For example, pairing whole genome sequencing
(WGS) and profiling by RNA-seq in breast cancer allows scientists to determine if somatic
point mutations are being highly expressed (8). Our goal is to identify any such changes that
may be important in the genesis of cancer, and in sarcomas in particular, in the hopes that
they may prove useful therapeutically.
1.2

Introduction to Sarcomas
Sarcomas are a relatively rare mesenchymal cancer, making up ~1% of all adult

tumors and 15% of all childhood tumors (9-11). They are most often found in the arms or
legs (60%), and chest or abdomen (30%), but they can be either soft tissue or bone
depending on the location (11).
The large majority of soft tissue and bone sarcomas do not have a known causative
factor. There are some isolated reports that suggest that soft tissue sarcomas may arise
near scar tissue, or at fracture sites, or that sarcomas of the bone may be more likely to
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arise from bone infarctions or radiation injury, but these appear to be the exception rather
than the norm. The foremost known causes are related to genetic susceptibility (which still
represent a relatively small number of tumors) such as individuals with germline TP53 (p53),
RB1, or NF1 mutations, but for the most part, the etiology of sarcomas, genetic or
otherwise, remains a relative mystery (11).
1.2.1 Sarcomas and clinical outcomes
Treatment for patients with advanced-stage sarcomas has not changed dramatically
in the past 30 years (12). The primary options for treatment are surgery, radiation,
chemotherapy, and targeted therapy.

Surgery remains the most commonly accepted

therapeutic option, but requires removal of healthy tissue with margins as wide a 1 cm
because even microscopically small portions have been associated with recurrence,
metastasis and death (11). Under ideal conditions with low grade sarcomas, and removal of
all tumorigenic tissue, local control is about 93% (9). Clinicians are still searching for a
consensus as to the best chemotherapy and radiotherapy options (11), raising the
possibility that better molecular profiling to inform treatment options could improve
patient outcomes.
Without treatment, sarcomas are highly likely to metastasize and are considered
highly aggressive, accounting for a disproportionate share of mortality in young adults.
(SEER

Cancer

Statistics

Review

1975-2008;

http://www.seer.cancer.gov/csr/1975_2008/)(11, 13). In fact, the mean age of onset for
sarcomas, in part due to hereditary syndromes, is earlier than for many other types of
cancer (14). Therefore, identification of sarcoma-related genes, either germline variants, or
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acquired somatic variants, is considered vitally important for diagnostic testing to help
identify at-risk individuals, and for uncovering and developing potential therapeutic
avenues.
1.2.2 Challenges in understanding sarcoma etiology
One distinct challenge in identifying drivers of sarcomagenesis is the sheer number
of histological subtypes of sarcomas. According to the World Health Organization (WHO),
there are over 80 subtypes of soft tissue sarcomas, and over 60 subtypes of bone sarcomas
(11). Because sarcomas are both rarer tumor types, and because they comprise such a
heterogeneous grouping of tumors, it is challenging to isolate enough tumors of similar
subtyping to generate sufficient statistical power to identify drivers, often requiring
extensive collaborations. Moreover, these data are further complicated because not only
are sarcomas very diverse (numerous subtypes), but also each sarcoma is heterogeneous in
composition. Sarcomas are frequently composed of bone, cartilage, and fat (13), which may
further obfuscate and hinder identification of important genes for tumorigenesis,
particularly if a driver gene need only be present in one of these tissues.
Two prominent papers were recently published on soft tissue sarcomas (STS). In a
Cell paper, out of the Cancer Genome Atlas network (TCGA), the authors sequenced six
types of soft tissue sarcomas, the majority of which are leiomyosarcomas (LMS) and
liposarcomas (LPS) (10). LMS were again a focus in the second paper, from Chudasma et al.
and published in Nature Communications (15). Both studies found that adult STSs have
heterogeneous mutational profiles with copy number aberrations (CNA) consistent with
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chromothripsis being a common occurrence. CNAs tended to be deletions, rather than
amplifications, and the authors found relatively few point mutations (10, 15).
In particular, the data from TCGA suggested that some alterations may be sarcomasubtype specific. These differentiating features can range anywhere from genomic changes
(e.g. CNAs and point mutations), to changes in the transcriptome, methlyome, or protein
levels. For example, most LMS have elevated signaling in PI3K/AKT signaling, and over 70%
have at least shallow deletions in TP53, RB1, and PTEN. The majority of LMS also have
elevated miR-143, and miR-145. However, two subtypes of LMS, gynecologic LMS (ULMS),
and soft-tissue LMS (STLMS) have distinct differences in the methylome and in reverse
phase protein array (RPPA) analyses. ULMS showed hypomethylation of ESR1 target genes,
something not seen in STLMS. RPPA showed that the DNA damage pathway was more
active in ULMS over STLMS, but that the HIF1 inflammation pathway was more active in
STLMS over ULMS (10).
Taken together, these data implicate CNAs as a key player in both LMS and LPS, and
indicate sarcoma subtypes have distinct molecular profiles, which may drive therapeutic
approaches for clinicians in the future. Ultimately, the data suggest that all sarcomas are
not likely to share the same etiology and that sequencing of similar sarcomas may be
necessary to avoid confounding from multiple types of sarcomas.
However, the authors do note a role for point mutations in soft tissues sarcomas. In
addition to CNAs frequently occurring somatically in the MDM2-p53 and p16-CDK4-RB1
pathways, the most recurrently mutated genes across sarcoma types in both studies were a
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triumvirate composed of TP53, ATRX, and RB1, further suggesting that these genes (and
their pathways) play important roles in sarcomagenesis (10, 15).
1.2.3 Sarcomas and multiple germline drivers
The thrust of the previous works by the TCGA (10) and Chudasama et al. (15) focus
on acquired somatic changes. A third, slightly older study, by Ballinger et al. looked at
germline genetic risk factors for sarcomas (16). These included a mix of both sporadic and
familial sarcomas, across a broad spectrum of sarcoma types, including soft tissue and bone
sarcomas, with publically available Caucasian data used as controls to eliminate
polymorphic alleles from consideration. Using targeted exon sequencing of 72 genes,
selected for known impact in cancer, Ballinger et al. found that risk generally fell into two
groups: classic monogenic variation (~80%), such as p53 (1% of all sarcomas), and polygenic
rare variation (~20%).

Individuals classified as having polygenic rare variation had

comparable tumor-free survival to monogenic p53 variants, suggesting that two so-called
weaker effects can make up for one big one (16).
Given the limited gene set from targeted sequencing, Ballinger et al. do not identify
any specifically novel genes, but do observe 2% of sarcoma-patients to have rare germline
mutations predicted to be damaging in ERCC2. ERCC2 is a helicase involved in base excision
repair; the authors argue that it should now be considered a sarcoma susceptibility gene
(16). Ultimately, more than half of the patients had variants predicted to be deleterious,
and 40% of these (one-fifth overall) had mutations with known pathogenicity, suggesting
that additional genetic risk factors for sarcomagenesis have yet to be discovered.
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1.3

Introduction to p53
p53 is arguably the most important tumor suppressor gene and has been called the

“guardian of the genome” (17), and more recently, the “guardian of the epigenome” (18).
Over half of all cancers have alterations in it, and it is considered the most mutated gene in
human cancers (19). It has roles in numerous cancer-related processes, including cell-cycle
arrest and apoptosis. Moreover, germline mutations and deletions in p53 lead to LiFraumeni Syndrome (LFS), a rare cancer predisposition syndrome that has a high incidence
of sarcomas, suggesting that p53 may play a role in sarcomagenesis (20, 21). Probably in
part due to LFS, it is considered to be the strongest monogenic driver of sarcomas (16).
Conversely, based on publicly available data from cBio, p53 alterations are present in less
than 60% of sporadic sarcomas, and as low as 20%, (10, 15, 22-25) implying that disrupted
p53 may not be required for their formation, and that sarcoma etiology may be
considerably varied. More specifically, sarcomagenesis may occur by two divergent
mechanisms, one that is p53-mediated, and one that is p53-independent, and consideration
of only one of these mechanisms, such as in LFS tumors, with germline p53 drivers, may
improve detection of additional sarcoma risk factors. Normally, p53 abrogates tumor
growth in part by helping cells to sense cellular stresses such as hypoxia and DNA damage,
and limit cell proliferation under conditions where genomic integrity is likely to be
compromised. However, when p53 is lost, the loss of these protective aspects can lead to
the accumulation of oncogenic mutations, as well as unchecked cell proliferation, leading to
a positive feedback loop where these populations expand more rapidly, resulting in
tumorigenesis (17, 26).
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1.3.1 p53 and MDM2
p53 is known to be regulated by a variety of regulators, including the negativeregulator MDM2.

MDM2 is an E3-ubiquitin ligase that specifically ubiquitinates p53,

exporting it out of nucleus, and marking it for degradation (27-29). Moreover, MDM2, as a
p53-inducible gene, is closely correlated with p53 levels in normal cells. When working
appropriately, these combine to form an auto-regulatory loop, designed to maintain low
levels of p53 in the absence of stress. On the flip-side, during periods of stress and DNA
damage, p53 and MDM2 are both phosphorylated, preventing their interaction with each
other, thus stabilizing p53 (30-34). In some cases, this stabilization has been shown to be an
important step in tumorigenesis, particularly when there is mutant p53, such as in LFS (35).
In addition, work by several groups has implicated a polymorphism in MDM2
(SNP309) as a risk factor across several cancer types, including colorectal, breast, lung, and
brain among many others (36-39). In conjunction with LFS or in sporadic sarcomas, the
presence of the MDM2 SNP309 polymorphism appears to accelerate tumor formation (37,
40-42). The results of meta-analyses have only continued to affirm that there is evidence for
association between MDM2 SNP309 and the p53 R72P polymorphism, suggesting that
MDM2 may act as a modifier gene for tumorigenesis (29, 37).
1.3.2 p53 gain-of-function mutations
Although the majority of mutations in p53 are loss-of-function (LOF), several groups
have demonstrated that, contrary to expectation based on other tumor suppressor genes,
which only have LOF mutations, some p53 mutations result in gain-of-function (GOF) (43).
This idea was first noted when some tumors with point mutations in p53 were found to
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have elevated levels of p53 in cancer cells relative to controls (43, 44), suggesting that p53
must have acquired additional properties capable of aiding, rather than hindering tumor
progression. The majority of results have been established by overexpressing mutant p53 in
p53-null cells, with GOF features associated with elevated resistance to apoptosis (45-48),
cell migration and invasion (49, 50), or alternatively with cancer in animal models (43, 51,
52).
1.3.3 p53 mutation incidence
The majority of tumor-relevant mutations in p53 occur in the DNA binding domain
(DBD), which comprises exons 5-8 of the gene. The World Health Organization (WHO)
based IARC database, which collects and compiles published data with p53 mutations at the
germline, and at the somatic level, show several hotspots (53).
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Figure 3: Compilation of published data containing p53 mutations, as generated by the
IARC database (53). Data on the left (A,B) composed of pedigrees with germline p53
mutations. Data on the right (C, D) represents individuals with somatic mutations in p53.
Data indicate that for both germline and somatic variants, most occur between exons 5-8,
and appear to have similar hotspots to one another.
1.3.4 Hotspot mutations in p53
These data also suggest one other way in which p53 differs from most other tumor
suppressor genes. In general, the mutational landscape for tumor suppressor genes and
oncogenes are considered to be different; tumor suppressor genes tend to have flat
mutational profiles, while oncogenes tend to have profiles with distinct, sharp peaks, known
as hotspot mutations (54). For example, in common tumor suppressor genes (TSG) like RB1
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and NF1, the profiles are relatively flat (Figure 4). In contrast, for oncogenes such as BRAF,
there are often hotspot mutations, i.e. nucleotides that are frequently mutated (Figure 4).
Thus, these data do not rule out the possibility that other cancer predisposing TSG will not
have mutation hot spots like TP53, or that some of these variants may be GOF mutations.
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Figure 4: Lollipop diagrams from cBio (22) depicting the mutation frequency across four
genes. Three are tumor suppressors (RB1, NF1, and TP53) and one is an oncogene (BRAF).
The profiles for the first two TSG are representative of most TSG. The third TSG, TP53,
appears to have mutation hot spots that are more consistent with a classic oncogene,
such as BRAF. Note that the scales are considerably different across the four genes.
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2 Li-Fraumeni Syndrome (LFS) and LFS-like (LFSL)
2.1

LFS
In order to better understand the underlying genetics and epigenetics behind

sarcomagenesis, we propose to use LFS as a model disorder. LFS is a rare, inherited,
heterogeneous, cancer predisposing syndrome caused by mutations in the tumor
suppressor gene p53 (70-80% of cases) (55, 56) with a high prevalence of sarcomas (20, 56,
57, 58{, 59). In a classic LFS pedigree (Figure 5), we see characteristic patterns of autosomal
dominant inheritance (cancer is observed in every generation) and anticipation (age of
onset for cancer gets younger for each generation, ranging from a lung cancer at age 61 in
the oldest generation, to a variety of cancers from roughly 30-50 years old in the second
generation, to sarcomas in the first two decades of life in the third generation).

Figure 5: Canonical LFS pedigree with a TP53 M133T mutation. The pedigree shows
characteristic patterns of autosomal dominant inheritance, anticipations, a broad tumor
spectrum, and a high prevalence of sarcomas, including a soft tissue sarcoma in the
proband, denoted by an arrow. Shaded circles represent cancer, with the age of diagnosis
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and cancer type noted below. p53 mutation carriers are denoted by a “*”, and individuals
with WT p53 are denoted by an “^”.
LFS is further identified by the high prevalence of sarcomas, which account for about
25% of all LFS-tumors (Figure 6) (53). The remainder of tumors seen in LFS covers a diverse
spectrum, including breast cancer, brain cancer, lung cancer, and adrenocorticoid cancer
(Figure 6) (53, 56). Given that p53 is considered to be the most preeminent cancer gene
(17, 19), it is hardly a surprise that p53 germline mutations predispose to so many types of
cancer.

Figure 6: Tumor incidence by type as compiled by the IARC p53 database for individuals
with germline p53 mutations (53).
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2.1.1 Clinical criteria for LFS
Several different clinical criteria have emerged for LFS over the years.
1. Classic LFS, first defined in 1988 (60), requires three criteria to be met:
•

Proband with a sarcoma before the age of 45

•

First-degree relative with cancer before the age of 45

•

Additional first degree relative with cancer before the age of 45, or a
sarcoma at any age

2. Chompret LFS (61, 62) requires one of the following to be met. Unless otherwise
stated, tumors in the LFS spectrum are considered to be: soft tissue sarcoma,
osteosarcoma, pre-menopausal breast cancer, brain tumor, adrenal cortical
carcinoma, leukemia, or lung cancer
•

Tumor belonging to LFS spectrum before the age of 46 AND at least one firstdegree or second-degree family member with an LFS-related tumor (except
breast cancer if the individual has breast cancer), before the age of 56, or
with multiple tumors

•

A person with multiple tumors, two of which belong to the LFS spectrum
(excluding multiple breast cancers), the first of which occurs before the age
of 46.

3. Eeles definition (63)
•

Two first-degree or second-degree relatives LFS-related tumors at any age

4. Birch definition (64) requires three criteria to be met:
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•

Proband with childhood cancer, sarcoma, brain tumor, or adrenal cortical tumor
before the age of 45

•

First- or second-degree relative with a tumor in the LFS spectrum at any age

•

First- or second degree relative with any cancer before the age of 60

Individuals and families meeting these criteria turn out to have genetic alterations in p53
(p53-LFS) in about 70-80% of cases (55).
2.2

Evidence for a Li-Fraumeni Syndrome-like disorder
However, several families that meet the clinical criteria for LFS appear to lack

mutations or alterations in p53 (56, 65), suggesting the presence of one or more additional
cancer/sarcoma-predisposition gene(s). Families meeting the LFS criteria are tested across
a barrage of tests to definitively rule out alterations in p53, including sequencing and testing
for copy number aberrations.

Notably, despite phenotypic similarities, the general

consensus seems to be that by definition LFS and LFSL should be considered distinct from
one another, that is, LFS-carriers must contain a p53 mutation (56, 66).
2.3

Alternative risk factors for LFS/LFSL

2.3.1 CHEK2
To date, no other mutations have been definitively associated with LFSL (56). In
1999, Bell et al. advanced the idea that CHEK2 could be a second LFS gene (67). They
identified a specific CHEK2 mutation (CHEK2 1100delC) that co-segregated with disease in a
family that met the criteria for classical LFS, but lacked a p53 mutation, as well as two other
families with different alterations in CHEK2 (67). Moreover, CHEK2 was known to be a cell
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cycle checkpoint kinase that interacted with, and stabilized p53, and the mutation itself,
which resulted in a premature stop codon, was found to abolish the kinase function of the
CHEK2. Combined, these initial data argued strongly for the probability that CHEK2 could be
an LFSL cancer predisposition gene.
However, subsequent data accumulation on LFSL families did not find CHEK2
1100delC to be a common cause of LFSL (68). Sequencing of additional LFSL families
revealed few families with CHEK2 alterations anywhere in the gene (69). Additional studies
failed to detect any mutations in CHEK2 in LFSL families across 48 total families (70, 71). A
fourth study, by Lee et al. in 2001 found three missense variants across 10 LFS and 49 LFSL
pedigrees, including a polymorphism (Ile157Thr), and two that were somewhat rarer
(Arg145Trp in a patient with breast cancer and a sarcoma, and Arg3Trp in a patient with
brain cancer) (72). Sodha et al. found CHEK2 variants in 3 of 26 families, but these included
a synonymous variant, an intronic variant which does not appear to impact splice sites, and
a 3-bp deletion in exon 3, thus continuing to suggest CHEK2 may not be an LFSL cancer
predisposition gene (69).
Expanding the pedigrees tested beyond LFS/LFSL for CHEK2 mutations, including in
familial breast cancer cohorts, did find excess risk for several cancers, including prostate
(73), colon (74), kidney (73), and breast cancer (74, 75), of which only breast is a canonical
LFS/LFSL tumor (56). However, they did not find similar upticks in sarcomas and adrenal
cortical tumors (73). The variant is fairly common in the general population (MAF is about
1%), and therefore present in some unaffected women, leading to the premise that it is a
low-penetrance breast cancer risk allele. Moreover, the deletion is enriched in breast
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cancer families that are BRCA1/BRCA2-negative (74). Therefore, despite some ambiguity in
the literature, the general consensus has emerged that CHEK2 should no longer be
considered a cause of LFS/LFSL (76).
2.3.2 p53 UTR
The majority of LFS-related research has focused on coding mutations in p53.
However, recently, Macedo et al. reported a rare germline mutation (rs78378222) in the
3’UTR of TP53 that was found in 7 LFSL probands (5.4%) and was correlated with reduced
expression of p53 (77).
2.3.3 Linkage indicates 1q23 contains an LFSL locus
An additional locus for LFSL was mapped by linkage to 1q23 (65). In this study,
linkage analysis using microsatellite markers was completed across 62 constitutive DNA
samples over four LFSL pedigrees, and mapped a 10-Mb region with a significant positive
LOD score (Figure 7). Moreover, although the authors assumed that these four families did
not necessarily have the same predisposing, locus, a heterogeneity LOD score, the highest
seen across the genome, suggested that two families (STS200 and STS027) contributed in
this region, with the STS200 family showing stronger linkage. As of December 2017,
according to the UCSC genome browser (hg19) (78), this region contains 148 genes and 5
miRNAs.
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HLOD=3.573
STS027=2.056

STS200 =3.455

Bachinski et al., 2005

Figure 7: Linkage map showing a high heterogeneity LOD (HLOD) score with contribution
from both STS200 and STS027 in the region. Used with permission from Dr. Linda
Bachinski.

3 Results
3.1

Quality Control and Choosing a Sequencing Platform

3.1.1 Sanger sequencing of functional positional candidate genes
To best identify putative germline cancer predisposition genes, we first used Sanger
sequencing to look for single nucleotide variants (SNVs) and splicing variants across 29
functional positional candidate genes: AIM2, ATF6, C1orf226, CADM3, CD48, CD244, CREG1,
DCAF8, DDR2, DEDD, DUSP12, DUSP23, ESR1, FCRL5, IFI16, KLDHC9, MNDA, NHLH1, NIT1,
NUF2, PEA15, PRKAR1A, PYHIN1, SDHC, SH2D1B, TAGLN2, UHMK1, USP21, VANGL2. Genes
were selected relative to known function and potential relevance to cancer.

Sanger

sequencing was performed across four primary individuals: STS200-000, STS200-017,
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STS200-032, each of whom had cancer, as well as a fourth, STS200-009, a married-in
founder, which served as a negative control (Figure 8).

Figure 8: Non-p53 LFS pedigree with linkage in 1q23. Initial Sanger sequencing was
performed on three individuals in the latest generation, all with cancer (STS200-032,
STS200-017, and the proband, STS200-000), plus a married-in control (STS200-009).
To analyze Sanger data, we used a program called “Mutation Surveyor” (79), which
automatically identifies variants using the chromatogram traces. To best ensure that we
were not missing anything, we ran the program with both a stringent, normal set of
parameters, as well as with a more relaxed set of criteria designed to limit false negatives.
Appropriate criteria were discussed with SoftGenetics after we discovered some
inconsistencies in their algorithms.
After manual verification using the chromatograms for clean, double peaks, we
identified 61 unique heterozygous variants across the three individuals (STS200-000,
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STS200-017, and STS200-032). However, none of the variants appeared to co-segregate
within these three individuals.
When no co-segregating mutations were observed in the Sanger data, we then used
454 sequencing data of these same four individuals to do longer, targeted sequencing of the
region. Robust analysis was complicated by an intrinsic drawback of 454-related data –
difficulty in interpreting homopolymers – and no strong candidates were identified.
3.1.2 Whole genome sequencing to identify putative mutations
To best identify putative germline cancer predisposition mutations, we chose to
employ next generation sequencing (NGS). Given the lack of strong candidates discovered
through both Sanger sequencing and 454-sequencing, we chose to leverage whole genome
sequencing (WGS) over whole exome sequencing (WES), because of the ability to evaluate
non-coding regions in addition to coding regions. Moreover, WGS offered an improved
ability to test for copy-number changes.
3.1.3 Establishment of a Sequencing Analysis Pipeline for STS200
Initially, we sequenced two individuals, STS032-011, and STS200-017 across both the
Illumina (GAIIX) and Complete Genomics (CGI, v. 2.0) pipelines to determine which
sequencing technology we wanted to move forward with. Subsequently, we sequenced one
individual on HS2000 (STS200-000), and five additional individuals from STS200 (STS200001, STS200-008, STS200-009, STS200-019, and STS200-032) via Illumina (H4000).
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3.1.3.1 Illumina Data
For Illumina-based data, we implemented an in-house pipeline consistent with best
practices according to GATK (80).

Figure 9: Final pipeline for WGS analysis, modeled after best practices according to GATK.
Briefly, for GAIIX, HS2000 data, we wrote some custom scripts to separate out FASTQ files
by lane. Once separated, by machine and lane, fastq files were aligned using BWA-MEM
(81). The resulting SAM files were cleaned and marked for duplicates using Picard to
mitigate potential biases introduced during amplification. Samples were then realigned to
adjust for potential issues near indels, followed by base-recalibration using GATK (80). For
the initial comparative analysis between the two pipelines, variant calls were made via
UnifiedGenotyper (82), but the most recent and relevant analysis leverages HaploCaller and
joint genotyping to generate gvcf files (80).
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3.1.3.2 Complete Genomics Data
For CGI data, we used their pipeline. The CGI chemistry was unique in that it used
adaptor ligation technologies that introduced known 2-bp gaps into the sequence reads.
Because most existing tools were designed around Illumina’s more contiguous sequencing
and without explicit gaps, adaptation of existing tools to CG data was problematic and
would have likely yielded less accurate results. The pipeline for Complete Genomics was
more of a black box, and tools to re-run the data ourselves were not provided. Therefore,
we used the variant calls generated by their internal algorithms.
3.1.3.3 Illumina vs. Complete Genomics
In order to determine which platform we wanted to move forward with, we
compared across a variety of metrics, including overall data quality, and ability to detect
known positives, including the p53-mutation, and the Sanger sequencing data, where
relevant. Preliminary analysis of the Illumina-based STS200-017 revealed that this data was
of poorer quality and established the importance of checking QC data.
3.1.3.3.1 Quality Control, GATK, Picard
All samples were examined across several quality control metrics to ensure the data
could be used for downstream variant calling. One sample, STS200-017 (Illumina) was of
demonstrably poorer data quality than the others.
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Figure 10: One Illumina sample shows an odd bimodal peak when looking at a plot of the
coverage. Single modal peaks without fat tails are the best.
Perhaps most strikingly, although most coverage plots depict a single, approximately
normally distributed peak, this “poorer” STS200-017 sample on Illumina produced a
bimodal peak (Figure 10).
Moreover, we also saw differences when looking at histograms of the quality scores
(of each base of each read). This difference was not apparent when looking only at
Illumina’s original quality scores but was when using GATK-based tools to recalibrate quality
scores empirically. Virtually all of the empirically determined quality scores for STS200-017
were less than 30, rendering it unsuitable for further use (Figure 11).
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Figure 11: Histogram showing frequency of bases (y-axis), with varying base quality scores
(x-axis) for two samples. Data on the top are the reported base quality scores by Illumina
for the good sample (left, STS032-011), and bad sample (right, STS200-017). These two
graphs are nearly identical. When adjusting empirically for accuracy (bottom), the poorer
sample fares significantly worse, with the majority of data falling below a q-score of 30.
We also reviewed additional metrics such as a histogram of base by cycle, and base
quality by cycle (Figure 12). Histograms of these data comparing STS032-011 to STS200-
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017, suggested that STS200-017 had steep drop-offs in quality near the ends of the reads at
higher cycle counts. These data may have contributed to the percentage of unmapped, or
singly mapped reads found in STS200-017, which was 5X higher than for STS032-011.

Figure 12: Quality control of base quality by cycle after recalibration shows dramatic
differences between the good sample (STS032-011) and the poorer sample (STS200-017).
In STS200-017 the second of the paired reads performs especially poorly, with empirical
scores being up to 10 worse than reported score.

28

We then checked to see if the bottom-line was affected and if these apparent
differences in quality impacted variant calls. Comparison of variant calling between a basic
variant calling algorithm setup for Illumina (via GATK, UnifiedGenotyper (82)), and Complete
Genomics (Complete Genomics internal pipeline), saw dramatic differences when
comparing SNVs for STS200-017 (51%) vs. STS032-011 (85%).
Taken together, these data suggested that the STS200-017 sample for Illumina
performed more poorly. Upon presentation to Illumina, they agreed to re-sequence a
second sample from the same individual (now on HS2000), and this second sample passed
all QC metrics and was in-line with the metrics generated for STS032-011 and other samples
sequenced at the same time with Illumina. These data strongly support the value of QC in
sequencing studies.
3.1.3.4 Comparison of WGS Technologies Relative to Existing Sanger Data
We next leveraged existing Sanger data for STS200-017 that arose out of the
functional positional candidate screen. Forty-eight variants in the Sanger data for STS200017 were identified using Mutation Surveyor, and were hand-validated individually by
checking the chromatograms for double-peaks in both the forward and the reverse strand.
Neither Illumina (44 SNVs)) nor Complete Genomics (45 SNVs) identified all 48 SNVs;
collectively they were able to identify 46 total SNVs. All “missed” SNVs were homozygous
for the reference by WGS. The data suggest that both Illumina and Complete Genomics are
approximately equivalent; they both identify the majority of Sanger-ascertained SNVs.
However, assuming Sanger sequencing as the Gold standard, the data did suggest that the
WGS might have contain some false negatives. We additionally checked the other sample,
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STS032-011, for which we had more limited Sanger data available, because it had a known
p53 mutation, for the expected variant, and confirmed we were able to identify the p53
R175H mutation.
3.1.4 Choosing Illumina as a Sequencing Platform
Several factors lead us to choose Illumina over Complete Genomics. First, the
majority of the Complete Genomics analysis pipeline is not well understood, and exists in a
black box. It requires the use of proprietary algorithms and analyses cannot be crosschecked with existing tools like BWA (81), Samtools (83), Picard (84), and GATK (80, 85).
However, at the time, we did not feel as if the variant calling for Complete Genomics was
sub-par or compromised due to these differences. Moreover, although Illumina did have a
slight hiccup during the initial phase of testing, subsequent resubmission of a different
sample from the same individual cleaned up the data and QC metrics well.
3.1.5 Additional Sequencing of LFSL Family Members.
Once we had selected Illumina to move forward with, we sequenced the proband
STS200-000 (HS2000).

However, these data produced no compelling co-segregating

variants between STS200-000 and STS200-017. To better ascertain co-segregating variants,
we then sequenced five additional individuals (STS200-032, STS200-019, STS200-008,
STS200-009, and STS200-001) at MD Anderson Cancer Center on HS4000 at 100-bp paired
end and analyzed according to the previously outlined pipeline (Figure 9)
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3.1.6 Establishment of a Variant Prioritization Strategy
Given the STS200 pedigree (Figure 8), we expected that a germline cancer
predisposition variant could be driving the cancer and sarcoma phenotypes seen in the
latest generation.

However, clinical testing suggested that a p53 mutation was not

responsible, suggesting the presence of a different, LFSL gene. We hypothesized that the
driver(s) behind LFS and LFSL would be etiologically similar.
Therefore, we established several criteria
(1)

We expected the variant to co-segregate between affected individuals
with cancer and obligate carriers because it resembles an inherited
cancer syndrome

(2)

The variant would be in 1q23, particularly given the relatively high LOD
score

(3)

The mutation would be an SNV (70%-80% of p53 LFS is driven by
missense mutations

(4)

The mutation would be predicted to be damaging, either through lack of
conservation, or through a big change in the amino acid properties

(5)

Lastly, we expected the variant to be rare because LFS is rare.

In summary, we initially focused on identifying co-segregating, rare (MAF<1%),
heterozygous, coding SNVs that were predicted to be damaging by both SIFT (<0.05), (86)
and Polyphen2 (PP2, >0.453), (87) that were in the linked region in 1q23.
Unfortunately, there were no variants that met these stringent criteria. To better
isolate putative mutations, we then relaxed the criteria in several ways (Table 1).
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Table 1: Table of various criteria used to identify putative cancer predisposition variants in
1q23. Under the stringent criteria, no putative variants were found. We incrementally
adjusted criteria to be more relaxed to better identify candidate mutations.
Stringent

More Relaxed

Minor Allele Frequency (MAF, 1KG)

<1%

<5%

SIFT/PP2 predictions

Both damaging

Either damaging

Co-segregation

Absolute

FamSeq (88)

Variant type

SNV only

SNV or indels

Location (via linkage analysis)

In 1q23

Whole genome

3.2 Identification of ARHGAP30 as an LFSL Predisposition Gene
3.2.1 Penetrance and Rarity in p53 and LFS
The presence of multiple LFS-related criteria suggests uncertainty in the field about
the best and most appropriate definitions for LFS. (60, 61, 63, 64) Inevitably, less stringent
definitions of LFS, such as under the Chompret criteria, where just a single individual can be
sufficient for an LFS diagnosis, imply that penetrance need not be significantly high in
LFS/LFSL families. Moreover, we posit that given the overall importance and prominence of
p53 in cancer, additional LFSL genes are likely to be less penetrant. In turn, this can lead to
greater ambiguity in clinical ascertainment, and underreporting, such that in sum, less
penetrant genes and mutations could be somewhat more prevalent in the general
population than would otherwise be expected based on LFSL (non-p53 LFS) incidence. If we
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do consider that such genes may be less penetrant, then it may make sense to adjust the
cutoff point for a MAF-filter.
3.2.1.1 Framework for Rare Variation
According to several databases, the most common LFS mutations are quite rare in
the general population. We leveraged the IARC (89) database to determine the most
frequently mutated codons, and then looked up the mutation frequency of variants in these
codons in databases such as Exome Aggregation Consortium (ExAC) (90) and ESP (91). In
Figure 13 we show a histogram of the most commonly mutated codons in families that
have been clinically ascertained as classic LFS (strictest criteria). For the nine most common
codons, I have included the codon number, and codon sequence. Above these, where
present, are the “MAF” of a variant in that codon as indicated in the ExAC database, as well
as the incidence. At the time of inquiry, ExAC contained 60,706 individuals. Despite the fact
that ExAC attempts to remove individuals affected by severe pediatric disease, it is clear
that p53 variants are occurring at some relative frequency. Under the exome sequencing
project, which covered 7,000 individuals, we saw exactly 1 individual with a mutation in
codon 273 (0.02%), while we saw 28 with a mutation in codon 337 (0.56%).
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Figure 13: Histogram from IARC (89) showing hotspot mutations in p53 at the codon level.
For the nine most commonly altered codons, the codon number is listed, along with the
codon sequence. Above that is a representation of the incidence in the ExAC database,
either as a percentage of all samples, or as the total number of individuals with a
mutation in that codon (in parentheses), indicating that these mutations are very rare in
the general population.
In contrast to this, recent research supports the idea that germline TP53 mutations
may be more common than previously appreciated based on LFS incidence. A perusal of
exome databases found 131 individuals (0.2% of samples) with TP53 mutations. These
mutations largely fell in the DNA binding domain (~80%), and included some that are known
to cause LFS, suggesting that numerous individuals may be carrying a non-penetrant
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deleterious p53 allele (92). Overall penetrance through close examination of the IARC
database was found to be ~80% (tumors before the age of 70), with varying penetrance
based on sex, age, and which p53 allele was mutated (93).
3.2.2 Allowing for more common variants identifies two variants that co-segregate
Given these emerging data, particularly that p53 variants may occur as much as 0.2%
in the general population, may mean that a MAF threshold of 1% is too conservative (92). In
order to cast a wider net, and account for the possibility that variable penetrance could
partially explain the results, we opened our MAF filter to account for variants with a MAF
less than 5%. Although this could potentially lead to the identification of a multitude of
variants, in practice maintaining the absolute co-segregation criterion is highly restrictive.
There are exactly two variants that both co-segregate with a MAF threshold of less than 5%,
and are predicted to be damaging by both SIFT and Polyphen2 (Table 2).
Table 2: Table showing all variants in 1q23 which both co-segregate, have a MAF < 5%,
and are predicted to be damaging by both SIFT and Polyphen2 (PP2).

SLAMF1 encodes signaling lymphocytic activation molecule 1. It is involved in the activation
and differentiation of immune cells and has roles in both innate and adaptive immune
response. As noted in Table 2, although the SIFT and PP2 scores are both promising (i.e.
predicted to be deleterious – scores are close to 0 and 1 respectively), the MAF is quite high
(close to 4% in the 1000 genomes project (94), 1KG)). When considered under the ESP
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(adjusted for ethnicity - the STS200 family is of Caucasian descent), this number is about
twice as high, 8.9%. Such a high MAF is perhaps more common than we would prefer for
what is theoretically a rare disease. SLAMF1 has not yet been associated with a disease.
Nevertheless, the role of the immune system in cancer is becoming increasingly apparent; it
is a new hallmark in the “Hallmarks of Cancer” v2. (2), thus making it a plausible functional
candidate.
NDUFS2 encodes NADH dehydrogenase ubiquinone iron-sulfur protein 2. NDUFS2
catalyzes NADH oxidation within the mitochondria (including ubiquinone reduction and
proton ejection). Much like SLAMF1, the MAF in both the 1KG and ESP (for European
Americans) are quite high for what is understood to be a relatively rare disease. Mutations
in the gene NDUFS2 have been associated with Mitochondrial Complex I Deficiency. This
mitochondrial disorder has heterogeneous presentation, including macrocephaly (large
head) and myopathies. However, cancer has never been associated with this disease,
suggesting that NDUFS2 may not be a strong candidate for additional follow-up.
To best determine if these variants were viable candidates, we performed Sanger
sequencing to (a) confirm the variant in the 7 individuals with WGS, and (b) to test for cosegregation in additional members of the pedigree. In SLAMF1, the married-in founder
turned out to have the mutation of interest. In NDUFS2, two obligate carriers and an
affected were WT for the variant. Thus, neither of these variants is of significant interest
moving forward.
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3.2.3 Less stringency in SIFT/PP2 finds four new variants for consideration
A second possibility is that SIFT (86) and PP2 (87) are imperfect prediction
algorithms and that requiring a mutation to be “damaging” across both algorithms may lead
to premature exclusion of variants. SIFT predictions are based on amino acid conservation
in closely related sequences. In contrast, PP2 emphasizes the impact of the change on
protein structures. In practice, SIFT and PP2 do not always agree with one another, and it
may be more worthwhile to consider variants predicted to be damaging by one or more
algorithm(s).

Moreover, known LFS variants such as p53 M133T sometimes may be

predicted to be relatively benign (initially the variant had a PP2 score of 0.148, but under
the most recent iteration, it is now 0.858). For example, if a cancer predisposing germline
mutation is human-specific; in this case, we would expect a SIFT score, which is based
primarily on conservation to be relatively high (i.e. benign). To cast the widest possible net,
we then changed the stringency in SIFT/PP2 to not require any thresholds, although we did
still require the variant to be exonic. In combination with the higher MAF threshold, we
found 6 total variants (Table 3), two of which were the same as in 3.2.2.
Table 3: Table of all variants meeting meeting the stringent criteria, except for rarity, and
SIFT/PP2 scores. All 6 variants are relatively common, and two are synonymous SNVs.

37

Of these, there were three new genes, IFI16, ADAMTS4 and OLFML2B. ADAMTS4
encodes disintegrin and metalloproteinase with thrombospondin motifs 4 and is known to
degrade aggrecan in cartilage and brevican in the brain and has a thrombospondin type
motif (TSR) that binds to the ECM. (95) ADAMTS4 is thought to possibly play roles in arthritis
(96) and potentially in glioma progression. (95) Similar to previous candidates, MAF for
these genes are comparatively high, around 5% and 10% for 1KG and ESP respectively, and
make the variant less compelling.
The variant in Interferon Gamma Inducible Protein 16 (IFI16) is synonymous, and like
the other variants considered so far, is reasonably polymorphic, but is actually one of the
candidate genes previously identified. IFI16 is a member of the p200 family, known to
inhibit cell cycle progression. Moreover, loss of IFI16 has been associated with breast and
prostate cancers (97).
There have been no papers published on Olfactomedlin-like 2B (OLFML2B), but
olfactomedlins have been implicated in development and organization of the nervous
system, and are generally thought to facilitate protein-protein interactions and cell
adhesion (98). Given the lack of immediately compelling candidates, we pushed forward to
consider additional variants rather than immediately jump to consider Sanger sequencing.
3.2.4 FamSeq identifies ARHGAP30 as an LFSL candidate gene
Without any particularly strong candidates so far identified in 1q23, we next
implemented FamSeq (88) to help identify additional co-segregating variants and reduce
the risk of false negatives. FamSeq leverages pedigree information to make more informed
decisions about variant zygosity. Effectively, FamSeq places a probability on a given variant
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call, including how likely it is to be heterozygous. If one or more individuals have the same
weak(er) variant call, FamSeq helps to isolate that variant and flag it for additional
consideration.
We then used FamSeq on the six affecteds/obligate carriers, requiring complete cosegregation of the same heterozygous mutation of interest. At this time, we did not use the
married-in control as a negative filter since this could be crosschecked later, and it appeared
the filtering criteria were already particularly stringent. However, under these conditions,
we found no new rare, or semi-rare coding mutations in 1q23, even when considering the
more lenient parameters discussed in 3.2.2 and 3.2.3.
One other possibility is that the family contains a(nother) phenocopy, or that one
affected individual could be homozygous, or even hemizygous for the mutation of interest.
It would be unlikely, but not impossible, for example, for both parents to have the
mutation, or for there to have been a gene conversion event prior to DNA sampling.
Instead then of asking FamSeq to identify all variants that had possible heterozygous
mutations in 6 of 6 affected/obligate carriers, we instead asked FamSeq to identify all
variants that seemed to be heterozygous in 5 of 6 individuals. Under the more relaxed
criteria listed above, we generated another list of candidate variants, with one notable
addition, a mutation in ARHGAP30 (Table 4).
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Table 4: Table of FamSeq-derived variants that are semi-rare, and meet strict SIFT/PP2
requirements.

The ARHGAP30 variant was found to be heterozygous in 5 of 6 affecteds/obligate carriers,
but in the sixth sample, the variant was found to be homozygous mutant (Figure 14).

Figure 14: Depiction of STS200 and WGS data, showing co-segregation of the ARHGAP30
mutation. One individual is homozygous (STS032-011)
ARHGAP30 encodes a RhoGTPase that has been linked to cancer and cell migration
(99, 100), with research indicating it acts like a tumor suppressor gene, making it a good
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candidate for LFSL. Although the MAF was somewhat higher than initially desired, the fact
that it was a tumor suppressor gene, and was predicted to be damaging (coding), and cosegregates implicates it as the most promising candidate identified. We then confirmed the
results, including the homozygous result by Sanger sequencing for these seven individuals,
indicating this mutation did co-segregate for these seven individuals. Subsequent follow-up
to sequence additional members of the pedigree confirmed that co-segregation was
otherwise complete. There was one seeming outlier: a bladder cancer patient (STS200102), who was WT for the mutation. However, based on the linkage, he shared very little of
the 1q23 haplotype and was expected to be a phenocopy, (i.e. WT for the mutation of
interest). Thus, these data further cemented ARHGAP30 as a candidate for future studies.
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Figure 15: Sanger sequencing of additional members of the pedigree confirms cosegregation of the mutation in ARHGAP30, including the homozygous result for STS200032. Based on the linkage, we expected one of STS200-108 or STS200-109 to be a
phenocopy, of which STS200-108 appears to be. Individuals with WGS are marked by
green boxes.
3.2.5 Co-segregation over the whole genome
In order to rule out the unlikely possibility that the linkage was incorrect, we
expanded the search to include variants over the entire genome. This time, because we
were not in the linked region, we changed the parameters to exclude STS200-019, because
she was a probable carrier based on linkage, but has not yet developed cancer. We
continued to leverage FamSeq to reduce the risk of false-positives, but decided to be more
restrictive using FamSeq by not allowing any phenocopies or homozygous alternate alleles,
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and requiring five of five individuals to carry the putative mutation. However, we continued
to use the less stringent criteria (MAF < 5%, SIFT or PP2 predicted to be damaging).
We found seven coding variants that met these criteria over the whole genome,
including the aforementioned SLAMF1 and NDUFS2, as well as two non-coding variants in
F11R and ARHGAP30 that were within 1q23.
Table 5: Table of variants that appear to completely co-segregate using FamSeq over the
entire genome.

To definitively determine if any of these variants were also candidate germline cancer
predisposition variants, we tested additional samples from the pedigree to see if they
maintained co-segregation.
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Table 6: Table showing that additional variants elsewhere in the genome identified by
FamSeq largely do not co-segregate when tested by Sanger sequencing.

Of these, only the variant in PKLR was found to completely co-segregate across the rest of
the STS200 pedigree. However, this exact variant is annotated in the ClinVar database
(101), as being associated with pyruvate kinase deficiency (PKD). PKD is an autosomal
recessive disease in which red blood cells break down too easily due to the lack of pyruvate
kinase. It has never been associated with a cancer phenotype.
3.2.6 No non-coding variants are immediately compelling
Next, we considered variants that were in 1q23, but were not in coding regions, such
as those in UTRs, introns, or that were upstream or downstream of the gene (with 2,500bp), in potential regulatory regions. There were 203 such variants that were not considered
to be polymorphic, the majority of which were intronic. However, we note that some of
these are likely to be false positives because they existed in near regions that were
homopolymers.
We then applied FunSeq2 (102), to better narrow down the list. FunSeq2 is a tool
that can help prioritize non-coding regions by looking at how often variants appear in them.
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The authors hypothesize that regions that almost never have a variant are somehow
protected and therefore may be functionally important. However, we didn’t find any
variants in these so-called ultra-conservative regions.
3.3

Cross-check of p53 confirms that p53 is not a genetic driver in STS200
We also exhaustively reviewed p53 to confirm it had no mutations, or copy-number

loss and was definitively WT. Moreover, as discussed in 2.3.2, recent research has identified
a p53 UTR-variant that co-segregated with disease in an LFSL family where p53 had been
previously ruled out (77). To check to see if the STS200 family contained this mutation
(rs78378222), we checked the WGS data, and used Sanger sequencing, finding that all
tested individuals were WT for the UTR-variant.
3.4

More in-depth investigation of “known” sarcoma risk factors
Several genes have been associated with sarcomas, either through a study of

individual subtypes, or through broader analysis of targeted sequencing. When they
analyzed 1,162 sarcoma probands, Ballinger et al. found that, overall, probands were more
likely to have multiple pathogenic variants relative to controls, and that these were best
clustered in TP53, ATM, ATR, BRCA2, and ERCC2 (16). To supplement these data, we
generated a genome-wide list of genes that have been previously associated with sarcomas
through both a literature search, and a perusal of the data put together by the WHO, across
both CN data and mutational data (11).
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Table 7: List of genes associated with sarcomas, either through hereditary cancer
syndromes, CN changes, or as fusion transcripts.
ACP5
ACTB
ACVR1
AIP
AKT1
ALK
ANTXR1
ANTXR2
APC
ASPSCR1
ATF1
ATIC
BCL2
BCOR
BLM
BRAF
BUB1B
C11orf95
CAMTA1
CCNB3
CCND1
CCNE1
CDH11
CDK4
CDKN1C
CDKN2A
CDKN2B
CHEK2
CIC
CLTC

COL1A1
COL1A2
COL6A3
CREB1
CREB3L1
CREBBP
CSF1
CTNNB1
CXCR7
DDIT3
DICER1
DUX4
EBF1
ERCC2
ERG
ETV1
ETV4
ETV6
EWSR1
EXT1
EXT2
FEV
FGFR4
FH
FLI1
FLT1
FOSL1
FOXO1
FUS
GLI1

GLMN
GNAS
H19
HAS2
HEY1
HMGA2
HRAS
IDH1
IDH2
IGF1R
IGF2
INI1
KCNQ1OT1
KDR
KIT
KRAS
LEMD3
LHFP
MAP2K1
MDM2
MEN1
MID1
MKL2
MTAP
MYH9
MYOCD
NBN
NCOA2
NF1
NF2

NFATc2
NFIB
NR4A3
NTRK3
PATZ1
PBX1
PDGFB
PDGFRA
PIK3CA
PLAG1
PMS2
PORCN
POU5F1
PRKAR1A
PTCH1
PTEN
PTEN
PTH1R
PTPN11
RANBP2
RB1
RECQL3
RECQL4
RET
ROR2
SDD
SDHB
SDHC
SDHD
SH3BP2

SMARCA4
SMARCA5
SMARCB1
SOS1
SP3
SQSTM1
SS18
SSX1
SSX2
SSX4
STARD13
T
TAF15
TEK
TFE3
TIE1
TNFRSF11A
TNFRSF1A
TP53
TPM3
TPM4
TSC1
TSC2
USP6
VGLL3
VHL
WRN
WT1
WWTR1

However, we did not find any other pathogenic variants in the germline in these sarcomarelated genes in any of the STS200 family members. It is possible that some of this is driven
by the fact that many of the listed genes are part of fusion transcripts.
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3.5

STS200 has no co-segregating indels or deletions anywhere in the genome
Lastly, LFS can be caused not only by SNVs in p53, but also by indels and CN changes

(56). To best determine if LFSL in the STS200 family could also be caused by either of these,
we leveraged both GATK and pindel (103) for calling indels, and ERDS (104) for CNVs.
However, we found no recurrent indels or CN changes suggesting that neither indels of CN
changes were responsible for LFSL in STS200.
3.6

Sequencing of additional LFSL pedigrees finds three other cases with the exact same
variant
To next determine if this variant was more widely relevant, we used Sanger

sequencing to test probands from other LFSL pedigrees (where p53 was ruled out) to see if
they had the exact same mutation in ARHGAP30. We tested 6 probands from Creighton
University, 27 probands from MD Anderson Cancer Center (including STS200), 9 probands
from Ohio State University, and 6 probands from the National Cancer Institute (NCI) for a
total of 48 probands. Of these, three additional probands contained the exact same
mutation in ARHGAP30, for a total of 4 of 48 (8.4%), suggesting that this mutation could be
a potential hotspot.
Interestingly, this mutation is somewhat analogous to hotspot mutations in p53. In
p53, several hotspot mutations occur in CpG sites, such as those at codons 175, 248, and
273, with deamination and G!A transitions being common (105).

Our variant in

ARHGAP30, GTTCGGC[G/A]AACCCAG, also occurs in a CpG site and may arise due to
deamination. This may, at least in part, explain why the mutation could be a hotspot,
and/or why the mutation is relatively common in the general population.
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3.6.1 Statistical case for enrichment of ARHGAP30 R806Q/R1017Q
To test statistically if these LFSL families were enriched for the mutation of
ARHGAP30, we used to a Poisson approximation based on two reported allele frequencies.
The dbSNP database contained the lowest reported MAF (0.86%), while the ESP (for
European Americans) contained the highest MAF (2.72%). Using this information, we
counted the number of cases we would expect to see on average, for 48 samples, and
computed a one-sided p-value to determine the likelihood that we saw 4 or more cases.
For dbSNP, this corresponds to a p-value of 8.7e-4, and for 4.4e-2 for ESP, suggesting that
these LFSL pedigrees are enriched for the mutation in ARHGAP30.
The result of having multiple families with the same exact mutation in a tumor
suppressor gene is unexpected, but not impossible. The majority of well-studied tumor
suppressor genes and oncogenes follow a specific pattern.

Oncogenes are typically

recurrently mutated at specific amino acids, while tumor suppressor genes have flatter
mutational profiles, with mutations, especially protein-truncation mutations, occurring
throughout the length of the gene (54). However, p53 is a notable exception for tumor
suppressor genes where hotspots for cancer predisposition are observed (1.3.4).
3.6.2 Co-segregation in non-STS200 families
Subsequent testing of these families was somewhat limited. Of the two other LFSL
families from MDACC, we had additional DNA from only one of the families (just the parents
of the proband). In this family, of which the proband had a Wilms’ tumor, one parent did
contain the variant of interest but had not (yet) developed cancer. The other was wild-type.
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3.6.3 Co-segregation is almost complete in the Creighton pedigree
The pedigree we received from Creighton University is substantial. We received both
DNA and formalin-fixed paraffin-embedded (FFPE) blocks from Dr. Lynch to test for cosegregation in this family. For the DNA samples, we used Sanger sequencing, but for the
FFPE blocks, we used pyrosequencing. Samples from this pedigree included FFPE blocks
from before 1972, and contained highly cross-linked and fragmented DNA, making Sanger
sequencing difficult. Therefore, using pyrosequencing, which amplifies a much smaller
fragment (~100-bp vs. 500-800-bp) was advantageous.

Even with the use of

pyrosequencing, we found that we needed to use a nested PCR in a clean room to generate
sufficient DNA from these samples and additional optimizations for FFPE samples as
described by Doyle et al. (106), including enrichment of the polymerase (106).
These data showed that co-segregation was almost complete in this family. Three of
four tested family members contained the exact same mutation, including two with cancer.
The fourth is a theoretical obligate carrier. She has not yet developed cancer, but had two
children with breast cancer (F, diagnosed at 35 y.o., dead at 36 y.o.) and lung cancer (M,
diagnosed at 32 y.o. dead at 32 y.o.). We have requested a second sample from this
individual for retesting, but have not yet received it.
We received one FFPE tumor sample from Creighton University; when tested this
tumor had retention of heterozygosity (ROH). However, we note that loss of heterozygosity
(LOH) may not be required for tumorigenesis. First, given the limited number of studies on
ARHGAP30, it is not clear if the gene could be haploinsufficient. Secondly, in sequencing
both human and mouse LFS tumors with p53 mutations, it is clear that p53 LOH is less

49

common than otherwise appreciated. Therefore, we do not consider this single result
showing ROH to rule out ARHGAP30 from additional consideration.
To summarize, the same ARHGAP30 mutation is found across multiple LFSL
pedigrees, and appears to be enriched in LFSL families over the general population. For the
most part co-segregation is complete in the families we have tested so far. Taken together
these data suggest that this specific variant in ARHGAP30 is a strong candidate for a
putative cancer predisposition mutation, or at the very least, a modifier for cancer
predisposition.
3.7

Structure of ARHGAP30
ARHGAP30 has one canonical domain, a RhoGAP domain towards the 5’ end of the

gene (codons 34-182), and two primary isoforms, dubbed here as a long isoform (LARHGAP30) and a short isoform (S-ARHGAP30). The two isoforms differ from each other
only by a glutamic acid-rich repeat. The ARHGAP30 mutation is marked by an asterisk, and
lies just outside this region (at R806Q in the short isoform and at R1017Q in the longisoform).
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Figure 16: Depiction of important elements of ARHGAP30 in relation to the mutation.
ARHGAP30 has only one known domain. The long and short isoforms differ only by a
glutamic acid (E) rich element. However, the putative cancer predisposing mutation
(marked by an asterisk) lies outside this element.

3.8

ARHGAP30 acts like a tumor suppressor gene
There have been exactly two papers published on ARHGAP30 to date. Both papers

suggest that ARHGAP30 is a tumor suppressor gene with roles consistent with cancer (99,
100). In the first paper, the majority of figures lacked controls, and few conclusions can be
drawn from it. However, data with controls indicate that when WT ARHGAP30 (short
isoform) is overexpressed, PAE/PDGFRb cells are less spread out, and more rounded, and
therefore may have more migratory potential.
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Figure 17: Figure 3a from Naji et al. 2011. In the presence of the overexpressed short
isoform of WT ARHGAP30, cells appear significantly more rounded relative to untreated
controls, and may have more migratory capacity. Used with permission: Naji, L., D.
Pacholsky, and P. Aspenstrom. 2011. ARHGAP30 is a Wrch-1-interacting protein involved
in actin dynamics and cell adhesion. Biochemical and biophysical research
communications 409: 96-102. L/N 4294720235318.
The second paper, by Wang et al. is significantly more comprehensive (100). They
showed that ARHGAP30 was significantly downregulated in colorectal cancer vs. normal
tissues, and that it was consistently associated with poorer prognosis, having both larger
tumors and more advanced stages of cancer on average, ARHGAP30 was initially identified
via a microarray analysis of TCGA data in colorectal cancer.
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Figure 18: Figure 1a,c from Wang et al. 2014. a) qRT-PCR data showing ARHGAP30
expression was downregulated in colorectal cancer vs. normal tissues. c) Kaplan-Meier
curve showing that higher ARHGAP30 expression levels was correlated with survival.
Used with permission: Wang, J., J. Qian, Y. Hu, X. Kong, H. Chen, Q. Shi, L. Jiang, C. Wu, W.
Zou, Y. Chen, J. Xu, and J. Y. Fang. 2014. ArhGAP30 promotes p53 acetylation and function
in colorectal cancer. Nat Commun 5: 4735. L/N 4294720087364.
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Importantly, we note that ARHGAP30 and p53 mutations should not be considered
to be mutually exclusive. Under cBio (22), multiple tumors appear to have alterations in
both genes (Figure 19), including a very small subset of samples that have truncating
mutations in both ARHGAP30 and p53.

Figure 19: ARHGAP30 and p53 are not mutually exclusive according to data from cBio
Oncoprint (22). Only a close up of the data is presented.

3.8.1 ARHGAP30 has a role in cell proliferation and migration
Wang et al. tested the impact of stable overexpression of ARHGAP30 across three main
ideas: cell proliferation, cell migration, and apoptosis, finding that cells transfected with WT
ARHGAP30 grew more slowly, moved less relative to controls, and promoted apoptosis
(100).
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Figure 20: Figure 4a,b,c,e from Wang et al. 2014. (100) a) MTT assay showing proliferation
of LoVo cells is decreased when ARHGAP30 is over-expressed.

Moreover this

functionality seems to be independent of the GAP domain since the effect in the R55A
mutant, which has no GAP-relation functionality. b) HCT116 cells also grow more slowly
in a GAP-independent manner. c) Both LoVo and HCT116 cells showed increased
apoptotic activity when overexpressed, and e) decreased capacity to migrate relative to
controls. Used with permission: Wang, J., J. Qian, Y. Hu, X. Kong, H. Chen, Q. Shi, L. Jiang,
C. Wu, W. Zou, Y. Chen, J. Xu, and J. Y. Fang. 2014. ArhGAP30 promotes p53 acetylation
and function in colorectal cancer. Nat Commun 5: 4735. L/N 4294720087364.
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3.8.2 ARHGAP30 has a p53-dependent role in cell proliferation and migration
The authors also find that ARHGAP30 has p53-dependent effects. Ectopic expression of
WT ARHGAP30 significantly upregulates p53-target genes like p21, NOXA, BAX, and PUMA,
an effect that was also RhoGAP domain-independent in HCT116 cells. Moreover, when p53null HCT116 cells were used, this effect was abrogated, and p53 target genes were not
upregulated. These effects extended to proliferation (Figure 21j) and apoptosis assays
(Figure 21k) with no significant effects observed, thus suggesting that ARHGAP30 has p53dependent effects.

Figure 21: Figure 4.j,k from Wang et al. 2014 (100). J; In contrast to Figure 20b, in a p53
null HCT116 line, ARHGAP30 overexpression does not suppress growth. k; similarly, they
observe no changes in apoptosis in a p53 null context. Used with permission: Wang, J., J.
Qian, Y. Hu, X. Kong, H. Chen, Q. Shi, L. Jiang, C. Wu, W. Zou, Y. Chen, J. Xu, and J. Y. Fang.
2014. ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nat Commun
5: 4735. L/N 4294740034573.
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These data persisted in the context of DNA damage. qRT-PCR data showed that cells
treated with etoposide had upregulation of p53 target genes, and that this effect was
attenuated by knockdown of WT ARHGAP30. Moreover, chromatin immunoprecipitation
(ChIP) analysis of cells with ARHGAP30 knockdown and etoposide treatment found reduced
binding of p53 to p21, BAX, NOXA, and PUMA. This effect seemed to be driven by
acetylation of p53 at Lys382 (K382), which is known to activate p53.

Additional

experimentation found that this effect was abrogated by knockdown of p300, and that
under co-immunoprecipitation, ARHGAP30 can pull down both p53 and p300. However,
these p53-dependent effects were found to be long-isoform specific, rather than the shortisoform of ARHGAP30, suggesting a functional role for the glutamic acid rich element in the
carboxy terminus of the gene.

3.9 ARHGAP30 c.G161,017,761A/p.R>Q has cancer-like functions for both the
long isoform (p.R1017Q) and the short isoform (p.R806Q)
Given our strong genetic evidence, including co-segregation and recurrence,
implicating ARHGAP30 R1017Q/R806Q as a putative cancer predisposition mutation, as well
as the functional data presented by Wang et al. (100), we next tested if our mutation
conferred any cancer-like advantages when transfected in vitro. In line with previous
experiments, we first sought to test cell migration and cell proliferation.
We assayed several sarcoma cell lines, plus the HEK293T cell line as a transfection
control. In addition, we perused the Cancer Cell Line Encyclopedia (CCLE) (107) to look for
cell lines with no, or low expression of ARHGAP30 to better test the potential effects of the
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mutation, but weren’t able to find any. Therefore, we picked the cell line with sarcoma
lineage, and lowest expressing ARHGAP30, Hs 863.T. No CCLE cell lines had reported
mutations, truncating, missense, or otherwise in ARHGAP30.

Table 8: Table of sarcoma cells lines used for transfection, with p53 status and ARHGAP30
status included.
Cell Line

Tissue

p53 status

ARHGAP30 status

HEK293T

Kidney

p53 R280S (108)w

WT, Norm. Expr.

U-2 OS

Osteosarcoma

p53 WT

WT, Norm. Expr.

Saos-2

Osteosarcoma

p53 deletion homozygous;

WT, Norm. Expr.

c.1-1182del1182 (ATCC)
HT-1080

Fibrosarcoma

p53 WT

WT, High Expr.

Hs. 863T

Ewing Sarcoma

p53 WT

WT, Low Expr.

Given that LFSL arises out of a p53 WT background, we would certainly expect to see
an effect in cell lines with WT p53. However, because p53 mutations are so important in
the context of LFS, and because ARHGAP30 has been demonstrated to interact with p53, we
felt it valuable to concurrently consider the potential ramifications of cooperativity between
the two genes. Moreover, p53 null mice seemed to abolish the effect of ARHGAP30 across
several phenotypes (100).
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To generate the appropriate mutant plasmids, we acquired expression constructs for
the short- and long- isoforms from Origene and used site-directed mutagenesis to introduce
our putative LFSL mutation. After sequencing the WT and mutant plasmids to ensure the
appropriate sequence and mutation were present, we next tested transfection across both
Lipofectamine 3000 (LPF) and FuGene 6 (FG6), finding overall better results for FG6 (FG6),
especially for Saos-2. Indeed for Saos-2, when staining for ARHGAP30, we observed
practically no transfection when using LPF. For two other cell lines (HT-1080, 293T), we also
observed that FG6 appeared to transfect at higher efficiencies. However, for the fourth cell
line, U-2 OS, we observed the reverse; LPF appeared to perform better (Figure 22). For the
fifth cell line, with low-expressing ARHGAP30 (Hs 863.T), the cells did not survive
transfection with either FG6 or LPF and therefore could not be pursued further. Given that
we did see successful transfection with FG6 for U-2 OS though, to best include Saos-2, we
decided to use FG6 moving forward.
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Figure 22: Western Blot performed in conjunction with Kevin Tracy (CPRIT summer
student) comparing the efficacy of transfecting U-2 OS, HT-1080, HEK293T, and Saos-2
with either Lipofectamine 3000, or FuGene 6, across both wild-type and mutant
ARHGAP30 (long-isoform). Stained with an ARHGAP30 antibody specific for long-isoform.
Control was selected from a previous experiment with positive staining. The data suggest
that overall, cells transfected with FuGene 6 appear to uptake more of the plasmid and/or
produce more protein. This is especially true for Saos-2 (left edge of figure), where
transfection was almost non-existent when using lipofectamine.
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3.10 ARHGAP30 R806Q/R1017Q have increased migratory potential
To test migratory potential, we used a scratch assay.
3.10.1 HEK293T
In HEK293T cells, we observed that cells transfected with mutant ARHGAP30 appeared to
show increased migratory capability. Due to the nature of the cell line, during scratching,
cells came off in sheets, and were unable to limit the scratch to a single field-of-view.

Figure 23: Scratch assay of HEK293T cells, transfected with either WT or mutant LARHGAP30. Cells transfected with mutant ARGHAP30 had increased migratory potential.
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3.10.2 U-2 OS
U-2 OS cells are WT for p53 and therefore fall best in line with what we would expect to see
in an LFSL patient without inherited TP53 mutations. In these cells, we see the most
dramatic change of all tested cell lines when comparing the wound healing capability
between transfection with WT and mutant plasmids. Cells transiently transfected with WT
ARHGAP30 (both long- and short-isoforms) show limited ability to close the wound. In
contrast, the mutant L-ARHGAP30 shows pronounced ability to close the gap with the
shorter isoform showing more limited, but still significant ability to close the intervening
space (Figure 24). Given that U-2 OS cells are WT for p53, these data demonstrate that the
ARHGAP30 mutation is sufficient to generate an effect even when p53 is not disrupted,
including in an LFSL patient-related context.
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Figure 24: Scratch assay of U-2 OS cells shows dramatically improved ability to close the
gap when transfected with mutant ARHGAP30, particularly for the long-isoform compared
to WT-transfections.

63

3.10.3 Saos-2
Saos-2 cells are p53-null, but we again see increased ability of the cells to close the wound
under transient transfection of the mutant relative to WT controls, although this effect is
not as dramatic as in U-2 OS. One distinct difference here though is that the short-isoform
shows increased closure relative to the long-isoform (Figure 25). Given that Saos-2 cells
are null for p53, these data suggest that the effect is present even in the absence of p53.
Although the result is not as accelerated as in U-2 OS cells, taken together these data
continue to point towards a p53-independent mechanism.

Figure 25: Scratch assay of Saos-2 cells. Mutant ARHGAP30 was not able to close the gap
entirely over 48 hours, but did show increased movement relative to cells transfected
with WT ARHGAP30.
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3.10.4 HT-1080
Similar to U-2 OS cells, HT-1080 cells are WT for p53 (53, 107). However, in contrast to
previous data, the endogenously high ARHGAP30 HT-1080 cells closed remarkably quickly,
including when the WT-ARHGAP30 plasmids are overexpressed, having closed after just 24hours (Figure 26).

Notably, even the untreated (?) control (with endogenously high

ARHGAP30 levels) is able to somewhat close the wound (though not completely). Again,
mutant ARHGAP30 shows increased ability to close relative to WT transfections, but this
effect is somewhat muted given the rapid closing.

Figure 26: Scratch assay of HT-1080 data. Both WT ARHGAP30 and mutant ARHGAP30 are
able to close the wound over 30 hours. Mutant ARHGAP30 does lead to marginally faster
wound closure relative to WT ARHGAP30.
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3.10.5 Summary of wound healing experiments
These data can be summarized either qualitatively (as shown in Figure 27) or
quantitatively.

Figure 27: Qualitative description of the closure results across the four cell lines, and
various transfection conditions. More “+”, implies a faster closure rate.
Quantitative representation can be done in two ways. First, we can try to find the size
of the wound by finding the leading edges of the wound and using a lasso-type tool to try to
determine the most appropriate area. This approach has challenges when the leading edge
is not well defined – either from being slightly out of focus, or from live cells which are
migrating, but not part of a distinct edge. It also has the potential to be subjective. The
second approach uses a threshold tool; since cells are often darker than the unclosed
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wound, this fact can be used to identify the percentage of the field of view that is covered
by cells. This has the advantage of perhaps being more unbiased, and is better at picking up
lone cells in the middle of the wound, or at correcting for cases where cells may be
migrating more than proliferating (leaving some areas as being less dense).
We have used the first method, measuring the area every three hours, because we
found it to be less error prone given the quality of pictures that we obtained, but
quantification makes one simple fact clear. Despite efforts to the contrary, it is difficult to
create single scratches with the same exact width – see different starting points for %
Covered for various treatments (Figure 28).

Figure 28: Quantification of wound closure in HT-1080 cells.
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3.11 ARHGAP30 R806/1017Q proteins show increased proliferative capacity
3.11.1 HEK293T
Consistent with ARHGAP30’s status as a tumor suppressor gene, in 293T cells we observed
suppression of growth when cells were treated with WT ARHGAP30, but when treated with
mutant ARHGAP30 we saw although they did not confer a proliferative advantage relative
to a control, they did appear to abolish the slower growth rates observed when
overexpressing WT ARHGAP30.

Figure 29: Proliferation assay of HEK293T cells showing reduced growth rates in
conjunction with WT ARHGAP30 transfection. Cells transfected with mutant ARHGAP30
in contrast show increased proliferation.
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3.11.2 U-2 OS
In contrast, in U-2 OS cells, we saw a much more muted response, although the overall
phenotype is similar to 293T cells. Cells transfected with WT ARHGAP30 did grow more
slowly relative to a control, and cells transfected with mutant ARHGAP30 appeared to
abrogate some of that response bringing it nearly in line with the control, but not above the
control.

Figure 30: Proliferation assay of U-2 OS has minimal differences between the different
conditions. However, there do appear to be slight differences consistent with ARHGAP30
being a tumor suppressor gene, and the mutant abrogating some tumor suppressor-like
behavior via increased growth rates.
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3.11.3 Saos-2
Data for Saos-2 appears to run somewhat counter to the previous data. We saw a trend for
the long isoform that seems to be similar to that observed for 293T and U-2 OS cells, but
not for the short isoform. Namely transfection with WT ARHGAP30 suppresses growth,
while transfection with mutant ARHGAP30 leads to higher growth rates more in line with
the control. However, we note that making this assumption assumes that cells were seeded
at the same initial concentration at time of zero hours.

Figure 31: Proliferation assay of Saos-2 showing that mutant ARHGAP30 appears to have
an effect in the long-isoform, but not the short-isoform.
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3.11.4 HT-1080
Similar to the scratch assay, in HT-1080 cells, it is difficult to tease out a difference in
proliferation rates between transfecting with WT or mutant ARHGAP30 for both the short
and long isoforms.

Figure 32: Proliferation assay for HT-1080s showing minimal differences between the
various transfections.

4 Discussion
Co-segregation analysis was used to isolate a plausible LFSL gene. We identify a
reasonably rare, co-segregating mutation in 1q23 that is recurrent across multiple LFSL
pedigrees. Moreover, this gene has demonstrated significance in colorectal cancer in the
literature (100), and our functional evidence shows the mutation itself appears capable of
inducing cancer-like phenotypes such as proliferation and migration.
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The functional data presents an interesting picture when juxtaposed against the
results from Wang et al. (100). Previously, these authors showed ARHGAP30 overexpression
was found to have no effect on apoptosis, proliferation, and expression of p53 target genes
in p53 null HCT116 cells (100). This left one big arm of their functional work unexplored –
what happens to migration in an ARHGAP30 overexpression/p53 null background. If cell
migration is abrogated alongside apoptosis and proliferation in p53 null HCT116 cells, it runs
in direct contrast to what we observe in Saos-2 cells. In Saos-2 cells with the cancer
predisposing mutation, cells are able to close the cap relative to overexpression of WT
ARHGAP30. This suggests that not only does the ARHGAP30 p.R>Q mutation have a p53independent means of impacting tumorigenesis, but also that it may be a gain-of-function
mutation.
Consistent with this interpretation, we observe wound healing and proliferation
phenotypes across both S-ARHGAP30 and L-ARHGAP30, where as data from Wang et al.
(100) suggest that p53 acetylation is L-ARHGAP30 specific. If our mutation were to impact
phenotypes through acetylation, we would not expect to see differences in S-ARHGAP30.
Interestingly, the effect on wound healing is greatest in WT p53 U-2 OS cells, placing
further weight on a p53-independent mechanism for mutant ARHGAP30. However, we
acknowledge that some of this difference could be due to reduced transfection efficiency
(Figure 22), and/or cell properties. Gaps in wound healing are typically closed through cell
proliferation and/or cell migration and of the cells cultured, Saos-2 cells grew the slowest.
Our data from HT-1080 are curious. ARHGAP30 expression is constitutively high in
this cell line relative to other cell lines that we used (Figure 33), and has no known
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mutation in ARHGAP30 according to the CCLE (107). Given that ARHGAP30 is a putative
tumor suppressor gene, and the previous establishment that WT ARHGAP30 can negatively
impact cell motility (99, 100), we might expect these cells to have the most limited response
to the wound healing assay. Instead, they have the most pronounced effect, closing within
30 hours, perhaps suggesting that these cells have acquired some sort of escape
mechanism. Moreover, additional WT ARHGAP30 exacerbates the closure relative to notreatment controls, which, on its own, implies ARHGAP30 acts more like an oncogene in this
cell line. Data from the wound healing assay indicates that overexpression of the mutant
construct slightly improves closure relative to WT ARHGAP30, but overall these data suggest
that the contribution of ARHGAP30 to tumor etiology in HT-1080 may be considerably more
complex than first expected.
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Figure 33: qPCR data for several cell lines, showing that ARHGAP30 expression in HT-1080
cells are significantly higher than healthy skin fibroblasts, a colorectal cancer cell line
(HCT116) osteoblasts (hOB), or two osteosarcoma lines (U2OS, Saos-2).
In addition, we had previously begun to look at the potential effect of ARHGAP30
mutations on downstream effectors of p53 (Figure 34). These data were generated by Dr.
Yu Deng in the Krahe Lab. She used lymphoblastoid cell lines (LBCLs) from STS200, three
with the ARHGAP30 p.R>Q mutation, and one with WT ARHGAP30 (“009”). She cultured all
four lines, and then treated each with and without radiation. Focusing only on the
untreated samples, we see that as expected, levels of p53 are about the same across all
individuals. However, the levels of p21 are not the same. In patient-derived LBCLs with the
mutant ARHGAP30, we saw lower levels of p21. Thus, it is possible that ARHGAP30, in
addition to interacting with p53, may also be part of a p21, p53-independent.
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Figure 34: Western blot of p53 and p21. Data generated by Yu Deng, Ph.D. (A) Western
blot showing protein levels of p53 and p21 in STS200-derived cells. LBCLs from STS200
were untreated (-) or irradiated (+) to check for p53 acetylation in response to the
stressor. Concomitantly, we checked for a response in a p53 downstream target, p21. (B)
Quantification of the protein levels of p53 and p21 in non-irradiated cells shows reduced
p21 levels in cancer patients. ARHGAP30 genotypes are provided above/below patient IDs
to aid interpretation: AA – homozygous WT, AB – heterozygous mutant, BB – homozygous
mutant.
We next considered potential relevance to sporadic sarcomas.

Under cBio,

ARHGAP30 is recurrently mutated in just 0.7% of all samples, and our specific germline
variant has not yet been called in publicly available somatic mutation data. However, it
turns out that our mutation is assayed by SNP arrays. We worked with Dr. Keith Baggerly
and Dr. Ying Wang to acquire these data and to generate a list of tumors and their
genotypes. We sorted by genotype, letting the A-allele stand for the WT-allele, and the Ballele for the mutant-allele. We then counted total alleles, and ran a one-sided Poisson
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approximation to see how likely we were to uncover at least that many alleles. We ran
these data under two conditions, once for the lowest reported MAF (0.86%, dbSNP) and
once for the highest (2.72%, ESP-EA). At the lower allele frequency, multiple cancers
appear to be enriched for the mutation, but when using the ESP as a baseline, there is just
one showing statistical significance, colorectal adenocarcinoma (COAD). We further note
that for COAD tumors, there are seven tumors with a “BB” genotype, versus six with an
“AB” genotype – these data imply that LOH may be a reasonably common event in these
tumors.
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Table 9: Table showing allele incidence of ARHGAP30 c.G>A, p.R>Q in TCGA SNP array
data (data generated by the TCGA: “http://cancergenome.nih.gov”).

p-values are

calculated via a Poisson approximation to determine if we saw enrichment for the
number of mutant alleles relative to expectation based on MAF (dbSNP, 0.86%; ESP,
2.72%). Data highlighted in red have p-values less than 0.05.
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Despite these data, there are a couple of mitigating questions remaining to be
answered. First, the co-segregation analyses suggest that co-segregation may not be
canonically complete. However, we believe there are plausible, if rare, scenarios that could
explain these seemingly “outlying” individuals.
First, for the one individual in STS200 that is homozygous for the mutation of
interest (STS200-032), it is unlikely, but not impossible that she received a mutant allele
from both parents. Alternatively, she could have experienced an extremely early gene
conversion event that resulted in an extended stretch of LOH. To address this possibility we
used our WGS data and looked in the region near ARHGAP30 and plotted whether variants
were homozygous for the alternate allele (blue), or heterozygous for the alternate allele
(red). If the sample was homozygous WT, we left it white/blank. In this region, it does
appear as if the STS200-032 sample is on average more homozygous for the SNVs/SNPs
interrogated (Figure 35), though it impossible to say for sure. A third, related possibility is
uniparental disomy (UPD), in which two copies of the chromosome come from the same
parent. This may also help explain some of the other heterozygous mutations in this region
in STS200-032, the majority of which are rare. Unfortunately, to definitively distinguish
between all possibilities is impossible in the absence of an available DNA sample from the
mother.
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Figure 35: CIRCOS plot showing possible gene conversion event. Homozygous events are
in blue and white/blank. Heterozygous events are red. The majority of samples have
significant heterozygous variants in this region, with the exception of STS200-032. We
feel that this data could be consistent with a gene conversion event.
In addition to STS200, one other co-segregation question remains under
investigation. One theoretical obligate carrier in the Creighton pedigree did not have the
ARHGAP30 mutation. She had two children with LFSL-associated cancers (breast and lung
cancer, both before the age of 40). However, she is in a more distant branch of the
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pedigree, and it is possible that she has a second, non-ARGHAP30 cancer predisposition
gene. Alternatively, it is possible that the father may have carried a cancer-predisposing
mutation; however, no information is known about his family.
However, we do not consider the MAF a major sticking point.

As previously

discussed, emerging research suggests that germline p53 variants may be more common
than previously expected. Thus, it may be perfectly reasonable to have a more common,
less penetrant allele (p53 or non-p53), even for a rare disease. Interestingly, we do not
observe any variants in known cancer genes – this implies either that ARHGAP30 has the
potential to have a strong monogenic effect, or that there are additional yet to be
uncovered polygenic or modifier genes that further modulate sarcomagenesis. For example
MDM2 SNP309, with a high MAF, affects tumorigenesis (1.3.1).

5 Future Directions in ARHGAP30 R806Q/R1017Q
Our evidence strongly supports that ARHGAP30 and the p.R806/1017Q mutation is a
recurrent, co-segregating, cancer predisposition gene in LFSL families. However, we note
that these data do have some mitigating question marks. The variant is not overly rare,
putting it in line with a previous purported LFSL gene/mutation CHEK2 1100delC, and in the
STS200 pedigree has an unexpected outlier, a single homozygous case. Moreover, in the
one tumor we have been able to sequence, we were not able to detect LOH. However, we
feel that there are plausible explanations for each of these scenarios and thus do not derail
the underlying genetic and functional evidence presented. We further note functional
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experiments would best be done in backgrounds of null ARHGAP30 to determine if this was
a GOF mutation.
We propose two fundamental ways to move forward with this project: First,
sequence (non-p53) LFSL pedigrees lacking p.R806/1017Q mutations for additional
mutations elsewhere in ARHGAP30. If ARHGAP30 follows the pattern of other tumor
suppressor genes, including p53, it should have mutations elsewhere in the gene that also
give rise to LFSL. Identification of further families with additional mutations would greatly
strengthen the argument that ARHGAP30 is an LFSL, cancer-predisposition gene. Secondly,
explore the functional implications in vivo through the use of a mouse model. CRISPR
technology has greatly impacted the ease and feasibility of generating mice with single
point mutations such as in the ARHGAP30 RQ variant. Following generation of appropriate
mouse model and cohort with the mutation(s) of interest, we can the track and observe
tumor formation in the mice. Moreover, in conjunction with this, it will be important to
check for LOH in tumors, both in the mice, or in humans, where tumor samples are
available, to look for characteristic LOH.
We note that there are many other possible in vitro experiments that could be run,
to explore other potential functional implications. For example, we have not yet looked at
apoptosis, in which ARHGAP30 plays a known role. (100) More to the point, we have so far
focused on overexpression of ARHGAP30 in cells with endogenous ARHGAP30; therefore, it
may be worth interrogating the results in an ARHGAP30 null background, or comparing
results against the cell lines when ARHGAP30 has been silenced.

81

6 Introduction: Sarcomagenesis and Somatic Mutations
6.1 LFS is a model for identifying acquired somatic mutations in sarcomagenesis
Cancer has been attributed to a variety of factors, including germline cancer
predisposition mutations, as well as somatic alterations.

In the first portion of the

dissertation, we leveraged LFSL to identify a novel germline cancer predisposition mutation
in ARGHAP30. In the second portion, we leverage tumors from LFS patients, with known
p53 mutations, to address the potential contributions of somatic alterations. Despite the
ubiquity of p53 mutations in human cancers, some individuals in LFS pedigrees (with p53
mutations) do not develop cancer (56, 93), or develop cancer very late, suggesting that the
p53 mutation alone is insufficient for tumorigenesis and that additional, acquired somatic
changes are necessary. Thus, we propose to use p53-LFS as a model for identifying these
changes, particularly those involved in sarcomagenesis.
6.2

Sarcomas are incredibly diverse
The rarity, heterogeneous composition, and numerous subtypes of sarcomas have

complicated elucidation of genetic risk factors and driver mutations.

A recent study

implicates ATM and ATR as risk factors (16), but lacked the statistical power to definitively
determine one way or the other. Moreover, sequencing done by the TCGA has shown that
different sarcoma subtypes tend to have distinct mutational profiles across the genome,
methylome, transcriptome, and proteome (10), implying sample selection is critical to
achieve statistical power. Thus, researchers are faced with a conundrum – sequence many
more disparate sarcomas, and try to work around confounding from multiple subtypes, or
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attempt to acquire additional sarcomas of more similar subtypes, of which samples may be
limited, even in large consortiums.
6.3

Benefits and Disadvantages of working with Human-LFS sarcomas
Under LFS, sarcomas are a fairly common cancer, representing about 25% of all

tumors (13% STS and 10% OS, Figure 6) (53), suggesting perhaps that sarcomagenesis is
largely driven by p53.

However, p53

alterations are present in only about half of
all sporadic sarcomas (10), and data from cBio
seems to suggest that even this 50% number
may be somewhat of an overestimate
(depending on ascertainment) (Figure 36).

Figure 36: Five sarcoma studies have been
recorded in cBio, covering bone sarcomas (Ewing), and soft tissue sarcomas (mostly
liposarcomas and leiomyosarcomas). From left to right, these comprise 249, 265, 207,
107, and 43 samples. These data suggest that alterations in p53 are not particularly
common in sarcomas, topping out at ~60%.
We also leveraged cBio to check for tumors with alterations in any of MDM2, MDM4, and
TP53 with about 45% of sarcomas having an alteration in at least one of these genes,
including a high percentage with MDM2 amplification (Figure 37). Taken together, and
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considering the prevalence of sarcomas in LFS-patients/pedigrees, these data seem to
indicate a role for p53 in sarcomagenesis.

Figure 37: cBio Oncoprint plot showing distribution of MDM2/MDM4/TP53 alterations in
sarcomas, covering 45% of tumors.
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Figure 38: IARC data. (89) Histogram of p53 mutations that have reported families
meeting the classical criteria for LFS (n=442). Of these, mutations in codon 248 (~14%) are
the most common, followed by mutations in codon 175 (~8%), analogous to codon 172 in
the mouse.
Working with LFS-sarcomas may harbor one distinct advantage over that of sporadic
sarcomas alone; they all involve disruption of the tumor suppressor gene p53 increasing the
likelihood that these sarcomas arise out of a p53-dependent manner. However, aside from
rarity, it is not clear if all p53 alterations should be treated equivalently – indeed different
p53 alleles have different penetrance (93). It remains to be seen if tumor etiology is similar
for mutations in p53 that are LOF (either by deletion, or point mutation) vs. GOF p53
mutations. Despite these potential issues, it is our long-term hope that identifying genes
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associated with sarcomagenesis in LFS patients, will also have relevance to sporadic
sarcomas, and other cancer types.
6.4

A Mouse Model of LFS May Help Identify Important Sarcomagenesis Genes
To overcome some of the limitations associated with sequencing only human

tumors, we elected to pursue and take advantage of a mouse model of LFS. Several mouse
models exist, including p53-/- mice in which cancer penetrance is 100%, with most cancers
occurring before 6 months. These mice had tumor profiles similar to that of LFS-patients
(109). However, since the majority of LFS patients have heterozygous point mutations, we
instead elected to pursue a different mouse model. This model, from Dr. Lozano, contains
the Trp53 R172H mutation that is analogous to the TP53 R175H hotspot mutation in
humans ((51) Of the p53 mutations associated with classical LFS, the TP53 R175H mutation
is the second-most common (Figure 38), and is known to be a GOF mutation). This mouse
model was also known to develop sarcomas (53%), particularly osteosarcomas (28%, most
frequent tumor type reported) (51).
The overall relevance of modeling the human TP53 R175H mutation can be further
emphasized with the use of a downloaded copy of the IARC database (53) for additional,
more granular analysis. These data include a “topography” column, which contains the site
of the original neoplasm, as well as the type and/or codon of the p53 mutation. We can
generate similar histograms as to Figure 38, except selected for tumors arising out of “soft
tissue” and “bone” – the majority of which are sarcomas, to see if germline R175H
mutations are prominent in these tumors. Although the overall mutation profile is different
than compared to all tumors (Figure 38), the histograms in Figure 39 indicate that
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alterations at codon 175 are still prominent in both osteosarcomas (Figure 39A) and soft
tissue sarcomas (Figure 39B).

Figure 39: Histogram of p53 mutations based on IARC data (53) and split by tumor
pathology (soft tissue and bone).
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6.4.1 Comparative approaches to identifying sarcoma drivers
One accepted approach to identifying drivers is to look for recurrent changes, either
through gains or losses, due to gross amplifications or deletions, or SNVs in critical genes.
These ideas underlie several efforts, including COSMIC, and TCGA to catalog somatic
variation across a wide-range of tumors (5, 110(111).
However, recurrence alone may be a poor metric. Some genes or genomic regions
may be, or appear to be, hypermutable, but may have little functional consequence. For
example, olfactory genes and large muscle genes (e.g. TTN) often appear to be represented
in lists of significantly recurrently mutated genes in cancer (112, 113). Respectively, these
gene families are either not expressed in tumors, or due to their size are likely to have
acquired somatic changes by chance alone, suggesting that recurrence alone is insufficient
or that it may misclassify some genes. Thus, separating out drivers from passengers
remains a key challenge.
Therefore, to better assist in separating passengers from drivers, we used a
comparative genomics approach, leveraging a mouse model of LFS (6.4). We hypothesized
that recurrent alterations in key genes and pathways, across both humans and mice, were
more likely to be functionally important drivers of sarcomagenesis.
Using the mouse model confers several advantages. First, it provides an avenue to
more readily generate LFS-associated sarcomas. Secondly, the mice will all have been
raised in the same, shared environment, the mouse facility. Thirdly, the mice will come
from reasonably similar backgrounds, and have the same exact cancer predisposition
mutation, potentially improving the ability to identify recurrent changes. Fourthly, by using
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humans and mice, it provides additional context for recurrent variation such as CNVs that
arise out of species-specific genomic context. Moreover, this comparative approach was
previously successful in acute promyelocytic leukemia, where authors also used a mouse
model to help implicate JAK1 V657F as being important in disease progression (114).
6.5

Complete tumor profiling as a goal
Although many sequencing studies have focused on looking at genomic information

via WGS or WES, it is clear that other changes, such as those in the transcriptome or
methylome may significantly contribute to cancer (5, 6, 115). In fact, these data can
support each other when done in concert, to provide a more layered, nuanced picture of
the tumor by testing, such as by testing to see if mutations are being expressed (114). In
addition, fusion proteins have been implicated in several types of sarcomas, such as Ewing
sarcomas (116), suggesting that sequencing DNA alone may miss key drivers. Transcriptomic
sequencing may be particularly key for identifying these fusion proteins.
6.6

Open-ended Expectations for Sequencing Sarcomas
For most cancers the number of driver mutations is thought to be between 1-10 (19,

54), occurring in a subset of reasonably predictable genes (e.g. TP53, NF1, RB1, PTEN,
BRCA1, BRAF, and so on). However, there is considerable ambiguity regarding the expected
mutational profile of LFS sarcomas. Many LFS-associated soft sarcomas appear to exhibit
chromothripsis and CNAs, particularly soft tissue sarcomas (10, 15), and exome sequencing
of osteosarcomas also reveals CNAs to be common (117, 118). On the other hand, several
genes with SNVs that may impact osteosarcomagenesis have been identified (117, 118).
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Other papers have identified point mutations and deletions in genes such as NF1, ERCC2,
and PTEN that should be associated with sarcomas (119, 120), further cementing the need
for a multi-omics approach.
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However, in many p53-associated non-sarcoma tumors, we observe a mutator
phenotype, related to p53’s function as the guardian of the genome, in which these tumors
appear

to

acquire

a

plethora

of

variants,

some

of

which

Figure 40: Tumor-free survival curve of p53+/H (n=50) and p53+/+ (n=20) mice from our
cohort, showing that that p53H/+ mice were more prone to develop tumors (p-value:
6.37-e7). Some p53+/+ mice developed lymphomas, particularly in the thymus.
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may only be passengers (121, 122). Thus it may be unclear what we should expect when
looking at p53-LFS sarcomas, chromothripsis, characteristic of sarcomas, or a mutator
phenotype consistent with p53 mutations, or some mixture of the two.

7 Results
7.1

Description of Mouse Cohort Results
Our original cohort consisted of 50 mice with the p53 R172H mutation, and 20 mice

that were p53 WT. These mice were followed for a period of up to two years, with
euthanasia performed for tumors, or other health conditions as needed. We collected
multiple tissues from every mouse for pathology (including vastus lateralis, duodenum,
pectoral and stomach muscles, diaphragm, kidney, spleen, heart, lung, liver, femur, and
spine), thus allowing us to interrogate tumors that may not have been obvious to gross
observation.
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Figure 41: Pie graph of tumor distribution in the p53 R172H cohort (n=50) shows a high
prevalence of lymphoma, with a variety of sarcoma types.
Overall, mice with the LFS cancer-predisposition did develop tumors and had
reduced survival relative to control mice. However, we did observe several p53 WT mice
that had to be sacrificed due to hyperpnea. In all such cases, mice were visibly hunched and
had lymphoma in the thymus upon dissection, suggesting that the p53 WT C57BL/6 mice
might have a predilection towards lymphomas, consistent with published results by
Donehower et al. (123).
7.1.1 Lymphomas and sarcomas were the most common tumor types
We sent all our tissues to Dr. Elizabeth Whitley (Pathogenesis, LCC) for full
pathology. The majority of tumors that we observed in our mice were lymphoma (including
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in some p53-WT mice), or sarcoma, with the majority of these being osteosarcomas and
histiocytic sarcomas. Consistent with the notion that sarcoma types could have different
etiologies, we attempted to minimize the types of sarcomas we observed during sample
selection.
7.1.2 Choice of sarcoma type for sequencing
The most common sarcoma type we observed in the mice was histiocytic sarcomas,
a neoplasia composed of hematopoietic cells, that has historically been classified as
lymphoma, and is typically ascertained only after extensive immunophenotypic
characterization (124), making it a less compelling candidate.

In addition, histiocytic

sarcomas are not considered to be among the most common tumor types associated with
LFS in humans; in fact, in the IARC TP53 database, there are no germline p53 variants
associated with histiocytic sarcomas.

Therefore, we instead chose to sequence

osteosarcomas and fibrosarcomas, leveraging additional samples that were previously
generated in the Krahe Lab with a p53 R172H mutation. In total, these comprised two
additional osteosarcomas, and four additional fibrosarcomas, for eight osteosarcomas, and
six fibrosarcomas in total for omics analysis.
7.1.3 List of mouse sarcomas for sequencing
The table below (Table 10) contains a list of samples, their ages, gender, types of
tissue sequenced, and whether or not the mouse was also diagnosed with lymphoma.
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Table 10: Table of Mouse Sarcomas for NGS. VL – vastus lateralis, FR – femur, FS –
fibrosarcoma, OS – osteosarcoma. Several mice were found to also have lymphoma in
addition to sarcomas – these are noted in the table.
Sample
F8-23
F1-13
F2-3
F8-17
F3-8
F2-4
F8-70
F8-51
F3-20
F7-12
F3-98
F8-49
F7-2
F3-35

Age (mo)
13.0
11.8
9.1
14.2
15.5
16.1
10.9
13.4
14.3
17.3
16.5
13.0
19.1
13.5

Sex
M
M
M
M
F
M
F
F
F
F
F
M
F
F

Normal Type
VL
VL
VL
VL
VL
VL
FR
FR
FR
FR
FR
FR
FR
FR

Tumor Type
FS
FS
FS
FS
FS
FS
OS
OS
OS
OS
OS
OS
OS
OS

Lymphoma
Yes
No
No
No
No
Yes
No
Yes
No
Yes
No
Yes
Yes
No

These data show one remarkable trend. The majority of fibrosarcomas were found in male
mice (5:1 male to female), while the majority of osteosarcomas were found in female mice
(7:1 female to male). We have no reason to believe that this is anything more than a
statistical anomaly, but may be worth continuing to monitor in future cohorts.

We

otherwise found no distinct trends for age and/or lymphomas
7.2

Mouse-specific variation necessitates the use of N/T pairs
Initially, we had hoped to use a pool of normal mice to serve as control tissues,

under the assumption that the mice were isogenic. However, during initial analysis of the
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normal pool, we found these mice had pockets of variation that were typically unique to a
given mouse, and could be due to being on a mixed background. These patterns were
visible grossly, at the chromosome level when looking at variant density plots, and by a
background check of the mouse.
When generating mouse models, there is risk for introducing additional variation
during the process, particularly when using embryonic stem cells (ESC) for targeting (125).
In this case, especially in early generations, the flanking regions around the mutation (or
gene) often come from the ESC, rather than the original mouse strain. This flanking region
can be reduced through backcrossing, but even after 10 successive backcrosses, as much as
1 cM on either side of the target (~40 genes on average) is likely to retain donor
sequence(125) (125), leading to the presence of passenger mutations around the region of
interest, particularly since variation is generally called against the background of the original
mouse strain. Thus, it is possible, if unlikely, that germline variation in these flanking
regions may contribute to the outcome, and strictly considering only somatic variation may
be somewhat of an oversimplification when trying to uncover genetic contributions towards
sarcomagenesis.
In fact, in sequencing normal controls from our p53 mice, we seemed to observe this
phenomenon. When we looked at overall variant density profiles for some mice in our
cohort (called against the reference, a C57BL/6 mouse), we found variation in the flanking
regions on chr11 (Figure 42) that was present in mice with a p53+/H background (red, blue),
but not WT-controls with wild-type p53 (orange, yellow, purple).
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Figure 42: Variant density plot (# of variants/100kb) from a pilot study designed to
determine if using a normal pool was reasonable under the hypothesis that the mice were
sufficiently isogenic. We sequenced two tissues from a p53+/H mouse, and three femurs
from three other mice with WT p53. These data show distinctly different variant profiles
for the p53H/+ mice vs. the p53 WT mice, and even hints that the p53 WT mice may not be
isogenic with each other
7.2.1 Multiple chromosomes appear to have non-C57BL6 background
Moreover, we found potentially confounding background from the 129-mouse in other
chromosomes as well. We worked with Dr. Benavides (MDACC – Smithville, TX; Research
Animal Support Facility – Smithville), to characterize the mouse background using strainspecific SNPs. A subset of chromosomes in the mice we tested had no 129-alleles, but a
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subset of chromosomes, such as 13, and 14 had fairly extensive contamination. Overall, the
data seemed to indicate that just over 80% of the alleles were from the C57BL/6
background.

Figure 43: SNP data checking the background of the p53 R172H mice showing that
although the majority of the alleles were from the C57BL/6 background (>80%), there
were some chromosomes that had extensive heterozygous alleles. The data also strongly
suggest that these mice should not be considered isogenic.
Consistent with these data, we also looked at variant density plots (line graph of
variants/100 kb) across other chromosomes across five tissues from different mice (Figure
44), finding that mice appeared to be less isogenic than originally expected. Several mice
had unique variation/variant profiles, such as “GL_1_N…” (grey) on chromosomes 1, 7, 11,
and 13, or “GL_7_N…” (orange) on chromosome 11.
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Figure 44: Variant density plots (# variants/100 kb windows), continue to support that
these mice are should not be considered isogenic.
These data support the previous evidence from the background check that these mice were
not isogenic, and necessitated the switch from a normal pool to only sequencing matched
normal/tumor pairs to better ascertain somatic risk factors.
For fibrosarcomas, we elected to use the vastus lateralis (VL, muscle) and for
osteosarcomas (OS), we used a femur (FR, bone) as a normal control. We expected that
such considerations matter less for the genomic analysis, but more for transcriptomic or
epigenetic analyses where tissue specificity matters more (126). In all cases, we chose to
sequence normal tissue that was distal to the tumor to better delineate acquired somatic
changes.
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7.3

LOH and Pyrosequencing

7.3.1 Initial WGS data suggests not all sarcomas have LOH
The general consensus in the field is that the majority of p53-tumors have eventual
LOH (127). However, in our pilot study, in which we sequenced 2 human tumors, and 2
mouse tumors by WGS, we observed one tumor with LOH and one with ROH for each
organism. Alerted to the possibility that LOH might not be as common as expected, we
used pyrosequencing to quantitatively determine the extent of LOH in our mouse tumors
and found two initially unexpected results. First, we saw LOH in some normal tissues.
Secondly, in contrast to the general consensus described in Rivlin et al. (127) of the majority
of tumors having eventual, we saw LOH in p53 in mouse sarcomas only about half the time.
However, we acknowledge that previously published LOH data by Lang et al. is also around
50% (51).
7.3.2 Some normal tissues appear to have LOH
In addition to pyrosequencing tumor tissues, we also sequenced the matching
constitutive tissues from the same mouse as controls, finding two outliers. We found two
femurs that appeared to be normal at gross observation, but had relatively advanced LOH
by pyrosequencing (Figure 45). In both cases, LOH was more pronounced in the tumor,
relative to the supposedly normal femur. Moreover, these femurs were not adjacent to the
osteosarcoma. One osteosarcoma was located in the ribs, while the other osteosarcoma
was in the left leg (with the femur being from the right leg).
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Figure 45: Pyrograms with peak heights. These data suggest that we had LOH in what
appeared to be normal femurs upon gross observation. Moreover, these femurs were
distal from the primary tumor site, suggesting that LOH may not be sufficient for
tumorigenesis.
To rule out the possibility that all constitutive tissues had this same behavior, we
pyrosequenced additional tissues from the same mouse, including the pectoralis muscle.
These other tissues all had ROH, suggesting that the LOH was relatively unique to the femur
(Figure 46).

101

Figure 46: Graphical depiction of pyrosequencing data of additional constitutive tissues in
mice with LOH in the femur. On the x-axis is a number-scale representing the %H-allele,
with circles trending towards the left side of the graph having greater LOH. Circles near
50% have ROH (i.e. have retained the WT-allele). These data suggest the majority of
normal (N) samples have ROH, with the exception of these two FR samples, which show
relatively advanced LOH, though not exceeding the tumors.
These data are consistent with the idea that p53 LOH at the Trp53 R172H locus is not
sufficient for tumorigenesis. However, because we typically send one femur for pathology,
and reserve the other for experiments, such DNA extractions, it is possible that the
sequenced femur had cancerous or pre-cancerous lesions that were not visible at gross
observation. We did not observe such a pattern to be the case for any VL/FS pairs; no VL
samples had LOH.
These data are juxtaposed against p53-/- and p53+/- mice. In p53-/- null mice, the
penetrance of tumors is 100%, suggesting that LOH alone would be sufficient for
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tumorigenesis.

In p53+/- mice, the data indicate p53 should be considered to be

haploinsufficient. Only half of all tumors in mice under the age of 18 months had LOH, and
this number dropped to just 15% in tumors over 18 months. (128) However, no such
comprehensive analysis of LOH has been done in p53H/+ mice and it is not clear if, or how
the GOF mutation may impact such behavior.
7.3.3 Use of toe tissue as normal controls
Due to observations that some tissues, which on gross observation appeared to be
normal, had LOH, we wanted to find better control tissues to best determine a baseline that
represented ROH.

We elected to use toe tissue, originally collected for genotyping,

between days 7-10 when it is still cartilaginous. Theoretically, these tissues should have had
minimal time to acquire additional somatic changes and therefore serve as a more
appropriate benchmark than constitutive tissues collected at time of sacrifice.
Data from toe tissue collected across our mouse tumors suggests that the totality of
the experiment and analysis has a slight bias for the mutant A-allele. Whether this occurs
during the PCR amplification, or as part of the pyrosequencing process, which is known to
favor the A-allele is unknowable. Using the toe data as a whole, we set up our own
classification scheme. We averaged the allele % from all toes, and then calculated a
standard deviation.

Anything within two standard deviations from the average was

considered ROH.
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7.3.4 Pyrosequencing shows that LOH occurs in only about 50% of mouse LFS-sarcomas
Pyrosequencing of all tumors and matched normals suggested that LOH was present only
in about half of all sarcomas (Figure 47), indicating the LOH (at the R172H locus) is not
required for sarcomagenesis. These data are also somewhat consistent with previous data
suggesting that LOH is less common in older tumors. Using an arbitrary cutoff point of 15
months, this provides a clear delineation in fibrosarcomas. For osteosarcomas the data is
less clear. There are two osteosarcomas (F8-49 and F3-35) at about 13 months that did not
appear to have LOH, and two older ones with more pronounced LOH (F7-12 and F3-98). We
also did not observe any trends for LOH as it relates to lymphoma status.
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Figure 47: Depiction of pyrosequencing results plotted against % of mutant and WT
alleles. Mouse name, tumor type (fibrosarcoma – FS, osteosarcoma – OS) sex, age at
sacrifice, and lymphoma status are listed at left-hand column. Data indicate where the
matching normal is (always femur, or vastus lateralis for corresponding tumors), with a
solid line indicating the extent of LOH in the tumor. Additional dashed lines account for
tumor purity as indicated by the pathologist where available. The black, solid vertical line
indicates ROH. Black dot-dash line bisecting graph in two separates out fibrosarcomas
from osteosarcomas. Table at top provides summary based on tumor type and ROH/LOH
status.
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8 Results: Sequencing of Mouse Samples
We then looked at several different kinds of sequencing. For DNA, we looked at WES
(at 40X/80X N/T coverage, Nimblegen 2.0, capture region 54.3 Mb) and low-coverage WGS.
For RNA, we were unable to isolate high-quality RNA from fresh frozen tissues. Despite our
best attempts to snap freeze, RNA appeared degraded after isolation. For methylation
data, we used reduce representation bisulfite sequencing (Illumina).

8.1

WES variant calling pipeline
We did all WES and somatic variant calling in-house according to best practices as

outlined by GATK. (80) We additionally used five different somatic variant callers, MuTect,
(129) MuTect2, (80) VarScan2, (130) Somatic Sniper (131) and MuSE, (132) again using the
default recommended settings. Historically, somatic variant callers have generally showed
poor agreement with one another, and are continuing to undergo refinement. (133) (134)
(135)
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Figure 48: Krahe lab pipeline for identification of somatic variation in WES data. We
found somatic variant callers to produce widely disparate calls – to compensate for this,
we looked at all somatic variants that were found by at least two algorithms to best
balance false positives and false negatives.
8.1.1 Filtering for high-quality somatic variants
In our pipeline, using the recommended best practices, and selecting only for
variants each considered to be high confidence, we saw poor agreement between the
samples when looking at somatic SNVs (Figure 49). A significant proportion of the lack of
agreement seems to be due to the high number of variants found by both mutect1 and
Varscan2, which call the most variants. Of all the variant callers, MuSE shows the greatest
overlap with other algorithms.

107

Figure 49: Representative Venn diagram of agreement between five different somatic
variant callers in our mouse samples. All variants were called according to best practices
as outlined in the documentation and were considered to be high confidence by the
individual variant caller. Overall, the key data trends that we observe are that Mutect1
and Varscan2 call the most variants, and that MuSE shows the most agreement with other
somatic variant callers.
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The lack of agreement underlies a key question: which somatic variant calls are true
positives? How should researchers balance retaining false positives, with true positives
occurring at lower allele frequencies (e.g. arising by tissue heterogeneity). Consideration of
variants found by all algorithms is almost certainly too restrictive – they represent, on
average, just 0.1% of all somatic variant calls (by any algorithm). In contrast, consideration
of variants found in any one algorithm may lead to spurious association. Brief visual
inspection indicates that these one-algorithm mutations contain a mix of plausibly true and
likely to be false variants.
To get a sense for an appropriate cutoff, we counted the number of variants found
by exactly one algorithm, by exactly two algorithms (any pair was fine), by any three
algorithms, and so on. On average, about 5% of total somatic variants are called are found
by 3+ algorithms, and about 10-15% of total somatic variants are found by 2+ algorithms
(Table 11).
Table 11: Table showing overlap of five different somatic variant callers. The top half
counts the number found by exactly 1, 2, 3, 4, or 5 algorithms for 16 N/T pairs across 14
mice. The second half translates these into percentages.

109

8.1.2 Somatic mutation burden in sporadic sarcomas
The most recent reported overall somatic mutation burden for human adult soft
tissue sarcomas is, on average, 1.06 per Mb, with the highest reported being 33.5 mutations
per Mb, where mutations are considered to be non-synonymous SNVs (10). Back
referencing the data against the cBio portal reveals that the samples with the three highest
mutation loads (>350 total mutations) have somatically acquired likely loss-of-function
mutations in p53: TCGA-DX-AB2E-01 (R342*, age 53, myxofibrosarcoma), TCGA-3B-A9HT01(W91*,

age

53,

leiomyosarcoma),

and

TCGA-DX-AB32-01

(L252del,

age

62,

undifferentiated pleomorphic sarcoma), consistent with the possibility that p53 LOF
alterations can increase mutational load. Four patients had somatic mutations at p53
R175H, analogous to the mouse model; these had 36, 59, 62, and 101 mutations, at ages 44,
73, 64, and 62 respectively (10, 22).
We then took variants that had been identified by two or more algorithms, and
annotated with ANNOVAR (136), SIFT, (86) and PROVEAN (137) to further select for nonsynonymous variants to see if our mice were in line with these data (Table 12).
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Table 12: Table showing the number of non-synonymous SNVs found in each mouse by
two or more algorithms (2+), or three or more algorithms (3+). Results are roughly
consistent with published data on mutation rates (by non-synonymous SNVs) in soft
tissue sarcomas.

At a capture region of 54.3 Mb in the mouse, if the same mutation rates hold in the
mice, we would expect to see an average of 58 mutations. To estimate an upper bound, we
took the highest mutational burden in an adult soft tissue sarcoma from the TCGA paper
(10), 33.5 mutations per Mb. Applying this rate to the mouse exome (33.5 mutations per
Mb * 54.3 Mb), gives an upper bound of 1,819 somatic mutations. Choosing either 2+ or 3+
is therefore roughly within the same order of magnitude.
Because we were unsure of how a germline GOF p53 mutation in the mouse could
contribute to somatic mutation rates, we decided that it was worthwhile to at least
consider somatic variants identified by 2+ algorithms, especially when using recurrence as
an endpoint.
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8.2

Whole Exome Sequencing Results

8.2.1 Recurrence in Somatic SNV Data
We initially looked at recurrence of SNVs across all mouse tumors, finding one
recurrent SNV, in Mroh2a.

This variant (c.C4088T, p.T1363M) was predicted to be

damaging (PROVEAN=-4.02, threshold < -2.5; SIFT=0.046, threshold < 0.05) but may be
polymorphic; it has an rsID but no reported allele frequencies. Secondly, we looked to see if
there were any genes that were recurrently mutated (using only variants predicted to be
deleterious). There were nine genes that recurred across three or more tumors (Table 13).

Table 13: Table of recurrent somatically mutated genes in mouse tumors (three or more
tumors). For a gene to be considered, it had to have a mutation predicted to have
functional consequence. Shading indicates where two comparisons for the same tumor
were made, one to a femur (FR), and one to a muscle (VL).
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With the exception of Arid1A, these recurrently somatically mutated genes do not appear
be well-known players in cancer. They are not found in any of our human-based gene lists
(covering cancer, the p53 network, and sarcomas). Therefore, these genes may represent
either good novel candidates to pursue further, or false-positives, arising perhaps out of
multiple testing of the entire exome.
8.2.1.1 Arid1a
ARID1A (in humans) is known to be a haploinsufficient tumor suppressor and is a
SWI/SNF chromatin remodeling gene that has been linked to several cancers, including
ovarian, gastric, and breast tumors, but not including sarcomas. In fact, in one paper by Wu
et al. the authors specifically claim they are not aware of any ARID1A mutations being
detected in human sarcomas (138). Moreover, the majority of cancer-causing mutations in
ARID1A that have so far been identified are stopgain or frameshift mutations (138), as
opposed to the non-synonymous SNVs we identified in Arid1a in the mouse.

Taken

together, these data raise some doubt as to whether or not these mutations could impact
sarcomagenesis, but do allow that ARID1A may be an intriguing, if not immediately
compelling, candidate for follow-up.
8.2.1.2 Mroh2a
Mroh2a is the most common somatically mutated gene across our mouse tumors.
These comprise seven non-synonymous variants, and one stop gain variant, some that have
been flagged as potentially being polymorphic.
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Table 14: Table of somatic variants in Mroh2a across all mice. Mice not listed here do not
have somatic alterations predicted to be damaging.

The function of MROH2A in humans has not been characterized and there have been no
published papers on the gene (https://www.ncbi.nlm.nih.gov/gene/339766). By cBio,
MROH2A has a somatic mutation frequency of just 0.1%, suggesting it’s not a superb
candidate for follow-up. But, examination of recently added TCGA sarcoma data finds that
MROH2A has a deep deletion in more than 5% of sarcomas (22).

Figure 50: cBio data for MROH2A (22). Most notably, sarcomas are the fourth most
common tumor with MROH2A alterations, with the majority of these being deletions.
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We also note that MROH2A is a relatively large gene, spanning almost 60 kb, and
1,800 codons. Therefore, it may not be unexpected to have acquired somatic variants by
chance alone. Despite this, the combination of it being the most recurrently mutated gene,
and recent CN data as seen in cBio make it an interesting candidate for additional functional
follow-up.
8.2.2 Inspection of multiple hits in the p53 pathway may be meaningful
Disruption of key pathways is often considered to be a hallmark of cancer (2, 54,
139). However, pathways often have built-in redundancies, and a single alteration may be
insufficient for tumorigenesis (140). For example, in renal carcinoma, loss of VHL or PBRM
alone are not sufficient for tumorigenesis, but co-occurring VHL, PBRM1, and SETD2
mutations are observed, the latter two of which are both involved in chromatin remodeling
via the SWI/SNF complex (141, 142).
This runs counter to the classic idea that mutations in the same pathway are
redundant and therefore unlikely, and the concept of mutual exclusivity for some gene pairs
(139). For example, in glioblastoma, TP53 and MDM2 were found to be mutually exclusive
(143).
Emerging data from melanoma presents a more nuanced picture. Classically, NRAS
hot-spot mutations are known to be mutually exclusive from BRAF hot-spot mutations at
codons 600 and 601. That is, each is strong enough on its own to lead to tumorigenesis.
However, some hotspot NRAS/KRAS/HRAS mutations have been shown to appear
concomitantly with recurring mutations in BRAF (not at codons 600/601), suggesting that
two alterations in the same pathway are possible or even required (144).

These
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observations indicate that two variants, with possibly weaker effects, could combine to
create a similar effect as one strong mutation.
Moreover, in malignant peripheral nerve sheath tumors (MPNST), a soft tissue
sarcoma, evidence suggests that activation of the Ras pathway takes multiple hits. In
addition to a germline mutation in NF1 (coupled with somatic loss), multiple MPNSTs had
additional somatic variants, predicted to be pathogenic (e.g. PIK3CA, KIT, PTPN11, and
FGFR1, among others) (145).

However, no single gene has emerged as being highly

recurrent in conjunction with mutant NF1. (145). Taken together, these data suggest that
looking for multiple hits in the p53 pathway (or any cancer pathway) has intrinsic value,
although this would best be done with a high number of samples to allow for potentially
weaker effects to be more evident.
8.2.3 Notable somatic variants in individual tumors
To better ascertain variants more likely to be true somatic mutations, we increased
the threshold for inclusion to require three or more algorithms. We took the following lists:
1. Krahe Lab p53 network genes (n = 131 genes)
2. Krahe Lab Sarcoma gene list (Table 7) (n = 147 genes)
3. Cancer Gene Census (146) (n = 609 genes)
to prioritize our search for known additional genetic risk factors. These lists are not
redundant with each other (Figure 51), with at least some of the differences due to how
the lists were curated. For example, some genes on the sarcoma list are based on only a
few case reports.
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Figure 51: Venn diagram of overlap of three gene lists: Cancer Gene Census, Krahe Lab p53
network, and Krahe lab sarcoma list. Figure not to scale.
Several mouse sarcomas had somatic mutations in known sarcoma- or cancer-risk
genes (Table 15). Investigation of p53 network genes found potentially deleterious alleles
in about half of tumors (Table 15), suggesting that the p53 network does not need to be
compromised in multiple places in the context of the Trp53R172H mutation.
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Table 15: Partial table of hits in known sarcoma, cancer or p53 network genes.

8.2.4 Notable germline variation in sarcoma-related genes
Given previous reports that some LFS patients may have multiple cancerpredisposing mutations or that differing p53 alleles have different penetrance (6.3), we
looked at the germline mutation profiles for each of the mice using variants called by
HaploCaller. We took the lists (146) previously outlined in 8.2.3 to prioritize looking for
known additional risk factors.
The majority of mice contain germline variants (non-synonymous, non-frameshift, or
frameshift) across three genes associated with sarcomas, Cdk4, Blm, and, Myocd the first
two of which are associated with osteosarcomas, the last of which is associated with LMS
(11).
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Figure 52: Germline variants in sarcoma predisposition genes in mice. These data are
compressed; all variants indicated are predicted to be damaging, but may not necessarily
be the same between mice. These data raise the possibility that they could contribute to
tumorigenesis. However, we observe no LOH of these variants in the tumor, suggesting
they may be haploinsufficient (in conjunction with mutated p53, or passengers. Key –
“0/1” indicates a heterozygous variant, with the reference allele (“0”) and the most
common minor allele (“1”). “./.” indicates insufficient data to make a genotype call, often
due to insufficient coverage. “0/0” indicates a homozygous reference/WT genotype.
The overall relevance of these mutations is difficult to determine. It is possible that such
germline variants contribute to the osteosarcomas observed in the R172H mouse (51), but
we do not see LOH at these positions in the tumor, suggesting that these mutations may be
haploinsufficient (in conjunction with mutant p53), or that they could be merely passengers.
We also do not observe any strong predilection for mice in our cohort with germline
variants in Blm and Cdk4 to develop osteosarcomas over fibrosarcomas, suggesting at the
very least they are not driving the sarcoma spectrum towards osteosarcomas.
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Table 16: Distribution of germline variants in Blm and Cdk4 by tumor type. Both genes
have been previously associated with osteosarcomas, but in our mice, show no
predilection towards OS over FS.

Moreover, it is not known if these variants may be polymorphisms (though they do not
carry dbSNP IDs).
We also examined our mouse cohort for non-recurrent variation, looking at each
mouse individually for mutations in key genes. Three mice from our cohort have germline
variants in sarcoma predisposition genes, and LOH in the tumor. RsH-F7-2 (OS) has a
nonsynonymous SNV in Chek2 that is predicted to be damaging (p.G263C, SIFT=0.04). Both
RsH-F7-12 (OS) and RsH-F8-70 (OS) have the same germline mutation in Bub1b, (p.L726I,
SIFT=0.033), a gene associated with embryonal rhabdomyosarcoma and aneuploidy in
humans (147), and LOH in the tumor. Interestingly, in humans, both CHEK2 and BUB1B
have been associated with chromosomal instability (147-150). Although alterations in the
two genes are not considered sufficient for chromosomal instability (CIN) on their own
(151), these mice all have the germline mutation in p53 (and LOH in the tumor). Thus, it is
probable that some germline variants in these genes contributed to tumorigenesis in these
mice, especially given their LOH in the tumors. While an accurate estimation of the
penetrance of these germline mutations in the context of an underlying p53 mutation is
preliminary, given the small sample size, no other mice had these exact same mutations
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(including as a germline mutation with ROH in the tumor), suggesting 100% penetrance for
these specific variants.
8.3

RNA-seq
Unfortunately, RNA extractions from fresh frozen tissues in the mouse produced

sub-par RNA for the majority of tumors and could not be subjected to RNA-seq
transcriptome profiling.
8.4

RRBS/Methylation data
RRBS data was analyzed in conjunction with Dr. Yue Lu. Data for RRBS was largely

high quality, but two samples did not pass QC (RsH-F2-4 FS, RsH-F1-13 VL). Therefore, these
were eliminated from further analyses.
8.4.1 Principal Components Analysis
Principal components analysis (PCA) of top 1% most variable sites, across all
samples, showed roughly three distinct groups (Figure 53). There was good separation
between normal femur (FR) and muscle (VL) samples, consistent with tissue-specific
methylation. Meanwhile, the majority of tumors (FS, OS) seem to coalesce into a third
group (towards the bottom of the plot). The OS that are not part of this third group do
group with their matched tissues, normal femurs.
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Figure 53: PCA of RRBS methylation data. Samples cluster into three distinct groups,
generally comprised of FRs, VLs, and tumors (OS and FS). A couple of OS do group with
the FR samples.
When we further plotted this PCA data against p53 LOH status from the
pyrosequencing data, we do not see much additional granularity in separating the tumor
samples (Figure 54). Tumors with more moderate LOH did seem to group together, but
there continued to be several tumors that appeared to have more significant LOH that
speckle the left side of the plot and were grouped with the femurs. These data also make
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clear that two presumably normal FRs that previously showed LOH by pyrosequencing still
appeared to group with normal FRs by methylation, suggesting that changes to the
methylome did not act as a precursor to tumorigenesis.

Figure 54: PCA analysis with the pyrosequencing LOH data laid over the top. There is
some modicum of grouping of the samples with pLOH that indicate the possibility of a
dosage effect, but one FS and three OS sarcoma samples dot the left side.
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8.4.2 Recurrence in the methylation data
Unlike for somatic SNV data, we see many of the same changes across different
mouse tumors from a methylation perspective. Due to tissue-specific differences, we
considered genes that were differentially methylated across all tumors, or across each of
FR/OS and VL/FS pairs. Multiple genes show significant hypermethylation across all tumors,
including Hic1 (hypermethylated in cancer, Table 17). However, of more immediate note is
that we observed substantial hypermethylation of Mir219a-2 across all mouse tumors.
Table 17: Methylation data in the mice shows significant recurrence. Overall, recurrence
was much higher via for hypermethylation vs. hypomethylation. Key: NS – not significant.

There have been no published studies on Mir219a2. However, in human cancers, a type of
sarcoma, malignant peripheral nerve sheath tumors (MPNST) are frequently associated with
deep deletions (>6%, Figure 55). Therefore, loss of Mir219a-2/MIR219A2 may represent a
novel key player in sarcomagenesis.
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Figure 55: cBio data of MIR219A2 (22). Although alterations are not particularly common
across all tumor types and studies (partially due to not being assayed), deep deletions of
MIR219A2 occur in almost 7% of MPNSTs, a type of sarcoma and mesenchymal tumor.
Several other genes also show hypermethylation across multiple tumors, including
Klf14, Cdx1 and Tcf15.
8.4.2.1 KLF14
KLF14 (Kruppel-like factor 14) has been identified as a tumor suppressor gene. In
mice, disruption of the gene leads to aneuploidy and spontaneous tumorigenesis,
particularly via centrosome amplification, a common event in cancer resulting the presence
of extra centrosomes. Klf14 directly targets Polo-like kinase 4 (Plk4), considered to be a
master regulator of centriole replication. In MEFs, Fan et al. found that loss of KLF14 led to
genome instability, and tumorigenesis, while gain of KLF14 led to cell cycle arrest (152). In
contrast to published work on KLF14, a big-picture view taken from the cBio database,
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suggests a different role. Instead, KLF14 appears to be amplified in the majority of cancers,
including sarcomas (Figure 56).

Figure 56: Alteration frequency of KLF14 in the top 35 tumor studies in cBio ((22)). Contrary
to published experiments, suggesting that KLF14 acts like a tumor suppressor gene, multiple
tumors have amplifications.
Therefore, given recurrence in our mouse data, and strong, published functional evidence
indicating a role in genome instability, considered a hallmark of many sarcomas, KLF14 may
be particularly interesting for additional follow-up.
8.4.2.2 Cdx1
CDX1 has a known role in gut homeostasis and induction of Cdx1 speeds up cell
proliferation in colon cells, suggesting an in vitro oncogenic role. Consistent with this, the
majority of colon cancer polyps have highly expressed CDX1 (153). Moreover, CDX1 is a
target of the oncogenic pathways Ras and Wnt/β-catenin pathway as well as being a known
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regulator of the Rho, Ras, and PI3-Kinase pathways (153). However, our data, which
indicate Cdx1 is hypermethylated across our mouse tumors, is not consistent with this view.
Recent research indicates the role of Cdx1 may be considerably more complex. For
example, although the majority of colon polyps have highly expressed Cdx1, about 20%
have lower expression of Cdx1 (154). Moreover, in mice without both Cdx1 and Cdx2,
tumors were found to be less invasive, and less differentiated (154). Coupled with LOF
function mutations also being found in other tumor types, such as carcinomas, this suggests
that CDX1 has a complex role in tumorigenesis, with both tumor suppressive and oncogenic
effects.
8.4.2.3 TCF15
_TCF15 (transcription factor 15) is found to be altered in about 1% of all tumors
catalogued by cBio (22). However, the available data somewhat contradicts each other – in
MPNSTs (a mesenchymal tumor/sarcoma), 6.2% harbor deletions. In contrast, in the TCGA
sarcoma (mostly adult STS) study, 2% of cases show amplification (5 cases), while 0.5% (1
case) show deletions. Additional data from a Memorial Sloan Kettering Cancer Center
(MSKCC) sarcoma study aligns with the TCGA data (1.2% (4 cases) have amplification, 0.3%
(1 case) has a deletion), potentially implying that TCF15 has tumor subtype specific
relevance. Given that we observe hypermethylation in our mice, our data most closely line
up with the MPNST data. However, this runs contrast to expectation relative to known
function. Previously, TCF15 has been associated with priming and accelerating pluripotent
cells for differentiation through repression of NANOG (155). Thus, a lack of TCF15, such as
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via hypermethylation could promote tumorigenesis through evasion of a more limited
replicative potential associated with differentiated cells.

9 Results: Sequencing of Human Samples
We received several human sarcomas from Dr. Strong, spanning a variety of p53 mutations
and tumor types (Table 18).
Table 18: Table of human LFS sarcomas and omics analyses performed. The majority of
WGS/WES data was generated on Illumina, except for STS170-038 (Complete Genomics).

We then looked at several different kinds of next generation sequencing (NGS). For
DNA, we looked at either at WGS, or at WES in conjunction with low-coverage WGS
(lcWGS). The majority of the normal/tumor pairs were assayed on Illumina at 40X/80X
coverage respectively. One sample was assayed on the Complete Genomics platform
(STS170-038). Analysis for Illumina samples was done with the pipeline outlined in Figure
48.
For RNA, we were unable to isolate high-quality RNA from fresh tissues, presumably
due to handling at the time of tumor extraction (and understandable prioritization of the
patient), but we were able to leverage FFPE tissues instead to acquire suitable RNA. For
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methylation data, we used the EPIC array (Illumina), and analyzed the data via the Rpackage minfi (156). Although we still considered recurrence as an endpoint, analysis of
both RNA and methylation data is further complicated by sample availability. For example,
for osteosarcomas, we would ideally sequence a tissue-matched normal bone, rather than
the muscle, due to tissue specificity in RNA and methylation. We can get around this by
sequencing more appropriate tissue controls (e.g. a normal osteoblast cell line), but then
these normal cell line controls lack the underlying p53 mutations present in the constitutive
tissue. Moreover, recurrence analysis is potentially confounded by the variety of underling
tumor types and germline p53 mutations, making it more likely that they could have
different underlying mechanisms of sarcomagenesis. Thus, it was also essential to consider
individual tumor analysis (6.2 & 6.3).
9.1

Analysis of human tumors alone reveals minimal recurrence in somatic mutations
Similar to mouse samples, we saw little overlap between the five somatic variant

callers. Using similar reasoning as 8.1.1, we used variants that were found by two or more
somatic variant callers.
Table 19: Table showing agreement between variant callers on the WES human data.
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Initial analysis of the human tumors for recurrent somatic changes in the DNA found no
overlap, either at the mutation or gene level, with the exception of p53.
The lack of overlap could arise out of several scenarios. First, given the variety of
germline mutations and tumor types, these tumors may have distinct etiologies from each
other. Secondly, tumor heterogeneity, clonality, and contamination from normal tissue
may obfuscate variant calling. Such mutations, occurring in just a fraction of the sample,
could be missed without using deep sequencing. Thirdly, tumorigenesis in these patients
may be driven by something other than somatically acquired SNVs or indels, such as CNAs
or epigenetic changes.
Therefore, to work around the fact that these potentially confounding variables as
best as possible, we examined each of the tumors individually for both germline and
somatic variants.
9.2

Some human tumors had additional germline variants in cancer genes
Analysis of germline variation did find two individuals with rare mutations in key

cancer-related genes. MGC900-001 (p53 R273H, breast cancer) had a mutation in the
breast cancer predisposition gene CHEK2 (p.R180C, MAF <0.01%) that was predicted to be
damaging (SIFT=0.18, PP2=1). Notably, CHEK2 had previously been associated with LFS
(2.3.1). A second, different individual (SMN119-000, p53 del ex 1-9) had a mutation in the
DNA repair gene MLH3 (p.V741F), that was also relatively rare (MAF ~2%), and also
predicted to be deleterious (SIFT=0.38, PP2=0.933). Although neither tumor showed of the
remaining WT allele, they may still contribute to the overall risk profile of the individuals on
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a mutant TP53 germline background. These data demonstrate the utility in looking not only
at acquired somatic mutations, but also at germline variation.
9.3

Individual human tumors had mutations in known sarcoma genes
Individual analysis of human tumors was useful not only at the germline level, but

also at the somatic level. Individual sarcomas had notable somatic mutations in sarcoma
related genes. One tumor had an early, heterozygous, somatic stop-gain mutation in PTEN
(p.G20X). Given that PTEN is a haploinsufficient TSG (157, 158), such a mutation would be
expected to have functional consequences. A second tumor had a stop-gain mutation in
NOTCH1. NOTCH1 is a transmembrane receptor that is typically considered to be an
oncogene, having been found to be up-regulated in synovial sarcomas and
rhabdomyosarcomas (159) and abnormalities in Notch signaling have been linked with
pediatric sarcomas (159).
However, in the majority of solid tumors, genetic alterations are rare in any member
of the Notch signaling pathway. Instead, deregulation of Notch signaling may play a larger
role in tumor maintenance (159).

Indeed, the role of Notch signaling is becoming

considerably more complex than initially suspected. For example, NOTCH1 has been shown
to be activated in some osteosarcomas (160), but in other cases, it has also been shown to
have tumor suppressive properties (161), suggesting a highly context-dependent role for
Notch signaling that may be either oncogenic or tumor-suppressive (161).
Overall, the lack of consensus in the human samples, possibly due to tumor type
heterogeneity, may argue for a different approach. Rather than use the human samples as
a discovery set, and use the mouse model to confirm recurrent changes, do the reverse.

131

Use tumors from the mouse model, where the mutation, tumor types, and environment are
more consistent, to look for recurrence, and follow-up in the human tumors.

9.4 Copy number analysis in human data
Alternatively, other types of alterations may explain the lack of consensus seen in
somatic mutations. Chromosomal instability is considered to be hallmark of sarcomas (10).
We worked with Dr. Nicholas Navin and a graduate student of his, Naveen Ramesh, to
generate copy number analyses using our WES and lcWGS data and their pipeline.
Consistent with previously published data, we observed copy number alterations, especially
across our tumors with point mutations in p53 (Figure 57). Our data is generally consistent
with reported data for sarcomas in that deletions are more common than amplifications
(10). Both MGC900-001 and SMN669-000 tend to have more deletions than amplifications,
but this was less true for SMN1012-000 and STS170-000, where amplifications may have
been more prevalent.
This effect was less pronounced, or even non-existent in tumors we sequenced that
had p53 deletions (Figure 58). These data may partially explain the lack of somatic point
mutations observed in our human tumor; larger events may be driving sarcomagenesis in
these patients.
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Figure 57: Copy number analysis of human tumors with point mutations in p53 indicates
significant copy number aberrations in human LFS tumors.

Data generated in

collaboration with Naveen Ramesh (Dr. Nicholas Navin lab). Grey lines represent ploidy
determinations, while blue lines represent copy number calls.

Red horizontal lines

represent 1N, 2N, 3N, and 4N from bottom to top respectively.

134

Figure 58: Copy number analysis of human tumors with deletions in p53 indicates
relatively few copy number aberrations in some human LFS tumors. Data generated in
collaboration with Naveen Ramesh (Dr. Nicholas Navin lab). Grey lines represent ploidy
determinations, while blue lines represent copy number calls.

Red horizontal lines

represent 1N, 2N, 3N, and 4N from bottom to top respectively.

9.5

Analysis of methylation data showed two distinct profiles
For human methylation data, we used Illumina’s HumanMethylationEPIC (EPIC)

array on the same DNA that we used to perform WES and lcWGS. To analyze human
methylation data, we used the minfi R-package and ssnoob pre-processing, followed by
bumphunter to find differentially methylated regions (DMRs) as described by Fortin et al.
(162).
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The method calls for a minimum default cutoff of 0.2 (i.e. a 20% difference in the
beta-values between normal/tumor), but for some samples this led to hundreds of
thousands of candidate bumps and long compute times. Since past a certain point, results
are less likely to be considered significant after adjusting for multiple testing and
permutations, the general consensus is to increase the cutoff (in our case up to about a 50%
difference in beta values), in order to drive the number of candidate bumps (without
consideration of p-value) down to ~30,000-40,000. We can see then some normal/tumor
pairs have very few DMRs (SMN1119-000, and STS170-000), while others must have
exceedingly high thresholds for the difference between beta-values (up to 54%, STS170038), as seen in Table 20.
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Table 20: Table of human samples with EPIC array data, indicating sex, age, and normal
and tumor tissue types, and the number of bumps and DMRs identified by the pipeline.
We note that the # of DMRs may be somewhat artificial since the pipeline uses # of DMRs
to help generate appropriate parameters. PBL – peripheral blood leukocytes, BR – breast,
FR – femur, MLPS – myxoid liposarcoma, OS – osteosarcoma, SC – sarcomatoid carcinoma,
SCC – spindle cell carcinoma, LPS – liposarcoma, MFS – myofibrosarcoma, RCC – renal cell
carcinoma.

However, some of, or perhaps even the majority of these DMRs may be due to tissuespecific differences (163). As an alternative, it may be better to ascertain DMRs against a
tissue-matched control from a different person, or cell line.
9.6

Recurrence analysis in human methylation data
Confounding information aside, there did appear to be some recurrence at the

methylation level. We found no DMRs that were consistent across all pairs, with the top five
hypomethylated genes including LHFPL2, PTPRN2, NRG1, ESR1, and JARID2, and the top five
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hypermethylated genes including FOXN3, TWIST1, TCF4, ST7, and MICAL3. However, we did
not see any overlap with the mouse data.
These methylation data represent an interesting cross-section of genes of the genes
that are hypomethylated, LHFPL2 is a transmembrane protein that is lightly altered when
examined in cBio (<10% of any tumor type affected), across both amplification, deletions,
and mutations, suggesting potentially tumor or environment specific effects. PTPRN2 is an
oncogene that has been associated with promoting migration in breast cancer (164), while
ESR1 is thought to act as a tumor suppressor gene (165). NRG1 has also been connected to
breast cancer where it has been shown to induce stem-like properties (166). Recently, Xi et
al. demonstrated that knock down of JARID2 inhibited invasiveness while overexpression
promoted in in bladder cancer cells (167).

Thus, many of the genes that are

hypomethylated appear to have oncogenic functions.
In concert with this, some of the hypermethylated genes generally appear to have
tumor suppressor-like functions. Loss of FOXN3 in colon cancer was found to activate betacatenin signaling and promote cell growth and migration (168). ST7 has been identified as a
tumor suppressor gene in prostate cancer (169). On the other hand, TWIST1 is more
commonly considered an oncogene that induces EMT (170). MICAL2 is also considered an
oncogene and has been associated with metastatic progression and a potential regulator of
EMT (171).
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9.7

Individual analysis in human methylation data
SMN669-000 had significant hypermethylation upstream of MLH1 (shore, p-

value=7.30e-4), and a CpG island of PTEN that is upstream of the transcription start site by
less than 1,500 bp (p-value: 5.26E-04).

10 Discussion and Future Directions
Overall, when looking at the data we saw little recurrence between human samples,
but significant recurrence between the mouse samples. This is consistent with the idea that
different p53 alleles have different penetrances, and considering that different sarcomas
may have different etiologies (10, 15, 172), this may not be too surprising. An overall
examination of the most recurrent hits, including prioritizing for variation found in both
humans and mice emphasizes this (Table 21).
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Table 21: Recurrence across both human and mouse sarcomas, across all data types.

Thus, these data underscore the power of our comparative –omics approach – not
necessarily because of the ability to cross-compare human and mouse data and determine
overlapping recurrence between the two, but because the mouse platform is so much more
stable. For rare diseases/tumors such as LFS/sarcomas, the reduction of confounding
factors (e.g. genetic heterogeneity) can be a powerful discovery space. For example,
MIR219A2 is recurrently hypermethylated in all mouse tumors, which we then found to
have a deep deletion in sporadic MPNSTs.
In contrast, many tumors across mice and human showed alterations at the
germline, somatic or methylation level in well–known sarcoma genes like PTEN. If these are
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sufficient on their own to lead to sarcomagenesis, it reduces the value in looking for
recurrence in trying to identify novel cancer genes. However, this does not mean that a
comparative approach is without merit. The Cancer Gene Census currently identifies 610
genes (https://cancer.sanger.ac.uk/census), and represents a good baseline for the lowhanging fruit. However, it is important to note that there likely are additional undiscovered
cancer genes that can be found, particularly using a case study approach. Increasingly, it
appears that cancer subtypes may have distinct etiologies, including in sarcomas (10, 15).
Additionally, one way to further identify novel cancer genes may be to look for
genes that cooperate with known players such as p53. Previously, we discussed the
possibility that while disruption of key pathways is often considered to be a hallmark of
cancer (2, 54, 139), pathways often have built-in redundancies, and a single alteration may
be insufficient for tumorigenesis (140).

Alternatively, it may be that additional p53

cooperating mutations may contribute to tumor type and/or spectrum. Although we found
no evidence for this in our data – we had no mutations/alterations that were found only in
fibrosarcomas vs. osteosarcomas, it is possible that a relative small sample size somewhat
obscures these data, or that considering multiple alterations may have more predictive
power.
Overall, our data agrees with previously published data – sarcomas have relatively
low point mutation burdens, but many have significant copy number aberrations (CNAs)
(10, 15). Intriguingly, in our data, patients with germline point mutations in p53, tend to
have more CNAs than those with large deletions. It is not clear if this could be due to
sample purity, or if p53-deletion sarcomas are simply more CN-stable. One other possibility
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is that the type of mutation may matter; while point mutations may be either GOF or LOF,
deletions are LOF only. This concept is not addressed in the TCGA paper and may be an
interesting point for follow-up.
Overall, the data from TCGA (10) highlight the need to consider tumor subtypes an
important factor in all sequencing analyses. This significantly complicates sarcoma research
moving forward, requiring expertise across a variety of fields, ranging from accurate
sarcoma subtyping from the pathologist to doctors to comprehensive sequencing and
analysis by bioinformatics specialists. Moreover, our data and published TCGA data indicate
that any of a number of factors from point mutations, to CNAs, to methylation profiles likely
contribute to sarcomagenesis.
If all sarcoma subtypes have different drivers, this may make it a cost-prohibitive
endeavor or time-insensitive project, due to the need to acquire dozens of samples of the
same type. Our data indicate a role for using a mouse model to identify potential sarcoma
drivers, but we have focused on osteosarcomas and fibrosarcomas – generating a mouse
model for even rarer types may not be possible.

Alternatively, given sufficient time

clinicians may collect enough samples from human patients to complete such a study.
Importantly though, we have used our data to identify potential impact players which are
both novel (e.g. MIR219A2, and with known roles in other cancers such as PTEN and
BUB1B).

Some of these have appeared to be common to both osteosarcomas and

fibrosarcomas, suggesting the potential that some drivers may be common to multiple
sarcomas. Thus, a comparative omics approach gives tremendous value to focusing on
sequencing more common sarcoma types first. Given that the end goal is to identify
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important genes, which in turn may impact clinical outcomes, this may be sufficient to begin
impact treatment.
Secondly, our data indicate that genetic mutations even in known sarcoma genes
such as PTEN are generally rare across our samples, underlying an important point – the
majority of sarcomas have low point mutation loads and instead are considered to have
significant copy number aberrations (10). In addition, some sarcoma subtypes, such as
synovial sarcoma subtypes had relatively uniform methylation profiles (10). We noticed
consistent patterns in our mouse methylation data, including some genes that were
recurrently hypermethylated and a PCA analysis that grouped both osteosarcomas and
fibrosarcomas together. Moreover several of the top hits in the human methylation data
had known functions in cancers. We highlighted four oncogenes that were hypomethylated
(e.g., PTPRN2, JARID2), and two tumor suppressor genes were hypermethylated (e.g.,
FOXN3, ST7). Thus, we feel that future sarcoma studies should consider focusing on
methylation data over genomic sequence analysis of point mutations.
We continue to look for ways to iterate over this process to better understand this
dichotomy of looking for recurrence first, or characterizing an individual tumor.

11 Conclusions
In conclusion, we have identified a novel germline LFSL mutation in ARHGAP30 that cosegregates with disease across multiple LFSL families (four total to date). Moreover, we
have demonstrated that this mutation, ARGAHP30 (c.G161,017,761A, p.R806Q/p.R1017Q),
has functional impact when overexpressed in vitro for both the short and long isoforms,
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suggesting that ARHGAP30 may have p53-independent functions. To further strengthen our
case, we are currently sequencing additional LFSL families to see if they contain other
mutations in elsewhere in ARHGAP30, and testing tumors to see if they have LOH. Both
results substantially strengthen the identification of ARHGAP30 as an LFSL gene and an
important gene for clinical testing for patients and families with LFS/LFSL phenotypes. Our
hope and intention is that this will allow for genetic testing and improved tumor
surveillance in individuals who have this genetic germline cancer predisposition.
Secondly, we have demonstrated the utility of a comparative –omics approach to
identify potential key players in sarcomagenesis. Recent research by TCGA emphasizes
tissue specificity in adult soft tissue sarcomas (10), and suggests significant value in
sequencing similar sarcoma types. We were able to leverage a mouse model of LFS to
identify two novel genes, Mroh2a, and Mir219a-2 as potential players in sarcomagenesis,
the latter of which has relevance to MPNSTs (145). Strikingly, although we observe few
overlaps in somatic mutations (at the base or gene level), we do observe significant overlap
at the methylation level, including between tumor types, suggesting that epigenetic
instability may be critically important, consistent with p53 as the guardian of the epigenome
(18). Across both our mouse and human tumors, we see recurrent epigenetic changes in
both novel, and known cancer genes.
However, our data also indicate that all types of -omics approaches can point to
alterations in key genes, and that these may be relatively private. In combination with a
large existing knowledge base in cancer, these “private” alterations may be considered
generally sufficient to explain tumorigenesis. We note that it is possible that these tumors
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have other mutations that contribute to cancer in smaller ways, or may be involved in
cancer initiation as opposed to cancer progression. However, that these mutations are
found in bulk tumor suggests that they occur in a large proportion of sequenced cells and
may be more likely to be key drivers rather than late-comers. Thus, recurrence should not
be used as the only endpoint when considering sequencing studies.
In conclusion, based on our collective data we would argue that to best understand
sarcomagenesis moving forward, one should focus on complete tumor profiling in as few
subtypes as possible. Furthermore, we would recommend an emphasis on evaluating CNAs
and methylation profiles, ultimately suggesting there is still strong utility in using LFS and
LFSL as model disorders to identify variation that is important not only for sarcomas, but
potentially other tumors as well.

12 Materials and methods
12.1 Subjects
Tissues and genomic DNA were kindly provided by Dr. Louise Strong’s lab (MD Anderson
Cancer Center), Dr. Henry Lynch’s lab (Creighton University), Dr. Albert de la Chapelle’s lab
(Ohio State University), and Dr. Mai Phuong’s lab (National Cancer Institute).
12.2 WGS/WES
WGS data were sequenced at 100bp PE across three platforms GAIIX (STS200-017), HS2000
(STS200-000, STS200-017, STS032-011), and HS4000 (STS200-001, STS200-008, STS200-009,
STS200-019, STS200-108) at 30-40X. Remaining normal/tumor pairs on mice were
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sequenced on HS3000 at 40X/80X respectively. Samples were analyzed according to best
practices as described by GATK or individual algorithms.
12.3 Sanger sequencing
Primers were designed in-house, and PCR performed according to standard protocols
(HotStarTaq Master Mix kit, QIAGEN). PCR products were cleaned using Diffinity RapidTIps
(Sigma) for small experiments, or via ethanol precipitation for full plates before submission
to the Sequencing and Microarray Facility (SMF) at MD Anderson Cancer Center.
Sequencing was generated in both directions. Traces were analyzed with Mutation
Surveyor.

hARHGAP30 R806Q F CCACAGTTTGCCAAGATGCC
hARHGAP30 R806Q R GGTCCTAATCACAGTCCTTCAC

hARHGAP30-UTR F

tgtaaaacgacggccagtTCTCTTCCTTATTTCCTGACC

hARHGAP30-UTR R

caggaaacagctatgaccCCCTAAGATACCTCCTGTCC

hF11R F

tgtaaaacgacggccagtTCTAAGGAGGAAGTAGGAAAGG

hF11R R

caggaaacagctatgaccTCTGCTCTTCCCAAGTTGTG

hMROH9 F

tgtaaaacgacggccagtATGACCAATATGAACCTCTTCC

hMROH9 R

caggaaacagctatgaccAAGACATTGTTGGACTTCCC
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hMUC5B F

tgtaaaacgacggccagtAGTTCCAAAGCCACTTCCTC

hMUC5B R

caggaaacagctatgaccCTGTAAAGCTGGTAGCTGTG

hNDUFS2 F

tgtaaaacgacggccagtAAGACTACAGGGTTTATATGGG

hNDUFS2 R

caggaaacagctatgaccCAGAAGAATTGCTTGAACCTG

hPARP4 F

tgtaaaacgacggccagtCCATAGAATAACAAACTCTGCGTC

hPARP4 R

caggaaacagctatgaccTCTGGATGGAGCATTGAAAGAG

hPKLR F

tgtaaaacgacggccagtTGATACAAATGGTAGGAGTGG

hPKLR R

caggaaacagctatgaccGCCCAGAGAAGTATGATGAC

hRETSAT F

tgtaaaacgacggccagtCCTGTCAGATAGAGGTTGGG

hRETSAT R

caggaaacagctatgaccTGTTTCTGCCCTTTCCTTGAG

hSLAMF1 F

tgtaaaacgacggccagtCAACACAAAGATGGAACGCTG

hSLAMF1 R

caggaaacagctatgaccATGCTTATGCTTGGAAGGGAG

hTP53-UTR3 F

tgtaaaacgacggccagtTTAAATCCCGTAATCCTTGGTGAG

hTP53-UTR3 R

caggaaacagctatgaccTTACATTCTGCAAGCACATCTG
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12.4 Mutation Surveyor
We ran both the default, recommended settings, as well as a set of hyper-relaxed criteria
that picked to pick some true positives at the cost of a lot of false positives.
Because some genes are highly homologous (e.g. PYHIN1), we supplied known sequence to
the program for such genes to force the correct mapping and eliminate erroneous variant
calls.
12.5 454 sequencing
Pyrosequencing was performed on a PSQ 96 machine, according to manufacturer’s
instructions. 20ng of DNA was amplified by PCR before use with pyrosequencer. For FFPE
samples, we used three times as much polymerase as we would for a normal PCR, and ran
the annealing step in the cycle for two minutes.

hARHGAP30 F TAAGACGACTCCGGGATCCAG
hARHGAP30 R

GACGGGACACCGCTGATCGTTTATCCCGAGCTTCTCGATCCT

hARHGAP30 Seq

TCAGTACAGGTCTGGGT

mP53H F

GGCCATCTACAAGAAGTCACAGCA

mP53H R

GACGGGACACCGCTGATCGTTTAAGGCGGTGTTGAGGGCTTA

mP53H Seq

GACGGAGGTCGTGAGA
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12.6 Cell lines
Four cell lines (HEK293T, Saos-2, U-2 OS, and HT-1080) were acquired from the
characterized cell line core facility at MD Anderson Cancer Center. The core provides
mycoplasma-free, and fingerprinted cell lines.

12.7 Mice.
Existing Trp53 R172H mice were bred to create a total cohort of 50 mice with a
heterozygous background. Twenty WT mice were kept as controls. Mice were monitored
continuously for tumors and other health issues, and sacrificed when necessary. Original
mice were received from Dr. Guillermina Lozano and are on a predominantly C57BL/6
background.
12.8 Genotyping
Mouse toes are collected at 7-10 days and digested with KAPA enzyme (Sigma) in 15uL total
volume. Final volume is brought up to 100uL. DNA is then assayed by PCR and run on an
agarose gel to look for band separation in heterozygotes.

mp53H F

ACCTGTAGCTCCAGCACTGG

mp53H R

ACAAGCCGAGTAACGATCAGG

12.9 Tissue collection
Mice were euthanized by cervical dislocation to best preserve RNA (over CO2 inhalation).
Tissues were then immediately collected by snap freezing in liquid nitrogen: pectoralis,
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vastus lateralis, femur, gastrocnemius, kidney, spleen, liver, stomach, duodenum or fixed in
paraformaldehyde for pathology: gastrocnemius, reproductive organs, digestive tract,
heart, lung, thymus, head/brain, kidney, liver, spleen, leg, sternum, spine. Lymph nodes
and tumors were collected where possible. All tissues were sent to Elizabeth Whitley
(Pathogenesis LCC) for pathology

12.10 DNA isolation
DNA was harvested from fresh frozen tissues using a mini-prep kit (Zymo) according to
manufacturers instruction, with one exception. Lysis was accomplished through gentle
rotation in a LabQuake shaker to avoid shearing of high-molecular weight DNA during
inversion, or vortexing. DNA was assayed for genomic integrity by agarose gel (0.8%, 20V),
and quantitated using PicoGreen (Molecular Probes)

12.11 FFPE RNA isolation
We cut 10, 10um sections with a microtome. RNA was isolated according to kit instructions
for ReliaPrepTM FFPE Total RNA Miniprep System.

12.12 Plasmids
We acquired constructs for the short isoform (NM_181720, Origene C/N RC208825) and the
long isoform (NM_0010255598, Origene C/N RC217735). Sanger sequencing was used to
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confirm the appropriate sequence in the original plasmid. Plasmids were expanded using
Ultra Competent XL10 cells (Stratagene), and DNA was isolated using
Maxi kits (QIAGEN), as per kit instructions.

12.13 Site Directed Mutagenesis
Plasmids containing the mutant were generated through site-directed mutagenesis (Agilent)
according to the kit, and checked for correct sequence via Sanger sequencing. Plasmids
used for mutagenesis:
F: CTCAAGGAGTTCGGCGAACCCAGACCTGTAC
R: GTACAGGTCTGGGTTTGCCGAACTCCTTGA

12.14 Scratch Assay
Cells were initially seeded in 12-well plates at ~60-70% confluency. Following overnight
attachment, transfection reagent (Lipofectamine 2/3000, or FuGene 6) and plasmid were
added at 3:1 ratio according to kit instructions. 24 hours post transfection, cells were
checked to see if they had achieved near 100% confluency. A single vertical scratch was
made with a P20 pipette tip. Cells were then washed, and imaged immediately with a livecell imaging microscope (Zeiss, 3i). Images were taken every 30 minutes for a period up to
48 hours.
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12.15 Proliferation Assay
Cells were seeded in triplicate in 96-well plates at low density at an average concentration
of approximately 10,000 cells/well. Once cells attached, we transfected according to the kit
instructions (Lipfectamine 2/3000, ThermoFisher; FuGene6, Promega). Cells were then
trypsinized, and counted twice/well using a hemacytometer and trypan blue (GIBCO). Cells
were counted approximately every 24 hours.

12.16 Western Blots
Protein extracts (30ug) from transfected cells were run on pre-made polyacrylamide gels
(Invitrogen), transferred to nitrocellulose (BioRad) and probed with antibodies for
ARHGAP30 (Abcam, ab101965) and FLAG (Sigma, F3165). Appropriate secondary antibodies
came from Odyssey. Blots were imaged on a Li-Cor (Odyssey).
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